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 Chemiluminescence is the light production directly from a highly exothermic chemical 
reaction by generating electronically excited species, and the light will be generated upon 
relaxation to the ground state. We utilize this light as the readout to construct imaging agents for 
reactive species. Chemiluminescence as an imaging modality has many advantages compared 
with current widely used imaging modalities, such as fluorescence and bioluminescence. The 
main advantages are the elimination of extraneous light excitation or genetic modification, which 
are required for fluorescence and bioluminescence imaging. Therefore, chemiluminescence as a 
imaging modality holds great potential for in vivo imaging. 
In this dissertation, based on different reactive species, several reaction-based imaging 
agents have been designed, synthesized, characterized and applied for cellular and in vivo 
studies. Structural modifications have been conducted to obtain better imaging agents. For 
example, the introduction of ortho-chloro substitution to the reactive handle lowers the pKa of 
the chemiluminescent scaffold, and the introduction of electron withdrawing groups at the para 
position helps to increase chemiluminescence emission. CHS-3, HyCL-2, and PNCL are 
chemiluminescent probes for hydrogen sulfide (H2S), peroxynitrite (ONOO–) and hypoxia and 




of interest. CHS-3 is the first reaction-based chemiluminescent probe demonstrating that 
chemiluminescence can be used as an imaging modality for in vivo imaging in wild-type 
animals. HyCL-2 with the hypoxia responsive para-nitrobenzyl alcohol functionality, has the 
ability to differentiate different tissue oxygenation and image tumor hypoxia. PNCL is an 
enhancer free chemiluminescent probe that features a ortho- acrylonitrile group to the isatin for 
enhanced luminescence emission and an isatin functionality as a ONOO– specific handle. PNCL 
has been applied for the detection of endogenously generated ONOO– in RAW 264.7 
macrophages. Finally, we are expanding upon the HyCL probe series with green and near-
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Let there be light!  
Chemiluminescence is the light production from a highly exothermic reaction that 
generates electronically excited species. Upon relaxation to the ground state, the light emission 
can be released. It is different from a conventional thermal reaction which normally releases 
energy in the form of heat. A chemiluminescent reaction has to be highly exothermic to raise the 
transition state higher than its electronically excited state to promote surface crossing (Figure 1-
1). Light from this unique reaction is sometimes called cold light which is emitted without the 
release of heat. Chemiluminescence exists in our daily life in various formats, such as glow 
sticks, bioluminescent bays, and fireflies (the latter two are characterized as bioluminescence 
because the processes take place in biological systems). As chemists, this glowing phenomenon 
is of particular interest. Chemiluminescence was first described by Eilhard Wiedemann in 1888 
as "Das bei chemischen Prozessen auftretende Leuchten würde Chemilumineszenz genannt",1 
which can be translated as “light emission from a chemical reaction should be called 
chemiluminescence”. This unique light production directly from a chemical reaction would come 
to offer us some useful applications.  
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Figure 1-1. Potential energy diagrams for (a) an exothermic reaction and (b) a chemiluminescent 
reaction.2 (S = starting material, I = reactive intermediate or transition state, P = product). 
 
1.1 Chemiluminescent systems 
Several chemiluminescent systems have been reported and some of them have been used 
for bioassays. In this dissertation, a brief summary will be given of some of the most used 
chemiluminescent systems and how light is generated from these systems. Luciferin/luciferase, 
luminol, acridinium esters, peroxyoxalates, and 1,2-dioxetanes will be discussed. 
 
1.1.1 Luciferin/luciferase system  
Luciferin/ luciferase systems are used by living organisms such as fireflies, bacteria and 
marine organisms to generate light,3 which is termed as bioluminescence. Bioluminescence has 
already been applied for the study of many biological processes both in vitro and in vivo.4 Even 
though there are millions of luciferase enzymes expressed by various species, only a few native 
luciferin/luciferase pairs have been identified and applied for bioimaging, including D-
luciferin/firefly luciferase (Fluc),5 Coelenterazine/Renilla luciferase (Rluc) or Gaussia luciferase 
(Gluc),6 and Vargula luciferase (Vluc).7,8 Although these bioluminescent systems differ in 
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unstable intermediates. In the firefly system, the enzyme luciferase catalyzes the oxidation of D-
luciferin in the presence of ATP, Mg2+ and O2 to generate an unstable highly energetic 1,2-
dioxetanone intermediate9 that decomposes to an electronically excited species (Scheme 1-1a). 
The emission of light is accompanied with the relaxation of this excited species. This system 
brought from nature has inspired scientists to adopt it as an analytical tool for biological 
research.  
D-luciferin is the most commonly used bioluminescent substrate for in vitro and in vivo 
imaging. Firefly luciferase catalyzes the light production from D-luciferin with light emission 
centered around 560 nm. Compared with fluorescence imaging, bioluminescence doesn’t require 
an external light excitation, which significantly reduces background emission and 
autofluorescence. In the last two decades, scientists have made significant progress in the 
development of better agents for bioluminescence imaging. Chemical modifications, genetic 
mutations and directed evolutions of bioluminescent substrates have been investigated to offer 
imaging agents with wavelengths ranging from green to the NIR range,10 and orthogonal 
luciferin/luciferase pairs can be obtained to image multiple analytes or multiple biological 
processes.11 The bioluminescence phenomenon has also inspired chemists to develop small-
molecule systems to mimic luciferin/luciferase oxidation and decomposition processes.12  
Although bioluminescence as an analytical tool has been frequently applied for biological 
research and in vivo imaging, some key obstacles that it faces are the limited number of 
luciferin/luciferase pairs that are available, and genetic modification to express luciferase 
enzyme is required which complicates experimental procedures and could potentially interfere 
with the biological processes of living systems. 
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1.1.2 Luminol  
Apart from luciferin/luciferase, luminol is one of the most used compounds for the 
generation of chemiluminescence. It has been utilized for crime scene investigation due to its 
reactivity towards iron in hemoglobin.13 Scientists also used this molecule for biological assays. 
Chemiluminescence can be triggered when it mixes with an appropriate oxidizing agent in basic 
conditions (Scheme 1-1b). The detailed process starts from the deprotonation of luminol, 
followed by one electron oxidation to generate luminol radical anion. This one electron oxidation 
can be achieved by the addition of a one-electron oxidant such as horseradish peroxidase, metal 
ions, or free radicals. The luminol radical anion can be further oxidized by reactive oxygen 
species, such as H2O2, and superoxide anion to form a hydroperoxide adduct. Subsequently an 
intramolecular reaction leads to the formation of an endoperoxide which can emit light upon 
decomposition. This system has been applied for designing a reaction-based probe for in vitro 
H2S detection by Pluth and coworkers.14 
 
1.1.3 Acridinium esters and peroxyoxalates  
Similar to luminol, light can also be generated from acridinium esters and peroxyoxalates 
(Scheme 1-1c,d). Light emission from an acridinium ester is triggered with the addition of 
alkaline hydrogen peroxide to form a four-membered peroxide ring, followed by the 
decomposition to initiate the light production. This light emitting system has been used for 
diagnostics and biomolecular labelling.15 As for peroxyoxalate, first reported by Rauhut in 1967, 
the light usually is generated as fluorescent emission by the dye added into this system.16 First, 
an activated oxalate reacts with H2O2 under basic conditions to generate a highly energetic 
intermediate, 1,2-dioxetanedione. This highly energetic intermediate decomposes with the 
  5 
release of energy which can be absorbed by a fluorescent dye incorporated into this system. This 
system has been used for the development of glow sticks and widely applied for analytical 
detection. Our laboratory has used this system as a platform to monitor H2O2 in human exhaled 
breath condensates using a smart phone camera.17 Although these systems can be tuned for 
efficient luminescent production, their biological applications are limited. The main disadvantage 
of these systems is the requirement of additional reagents such as H2O2 and a base, which can 
complicate the detection procedures and interfere with biological processes. 
 
1.1.4 1,2-dioxetanes 
Kopecky and Mumford reported the first synthesized 1,2-dioxetane, 3,3,4-trimethyl-1,2-
dioxetane, in 1969 (Scheme 1-1e).18 Luminescence emission was observed during its thermal 
decomposition at 60 °C in a benzene solution. A wealth of 1,2-dioxetane derivatives has been 
synthesized and reported since then.19 The thermal stability of these 1,2-dioxetanes differs 
tremendously from each other. 3,3,4-trimethyl-1,2-dioxetane decomposes quickly at room 
temperature.18 Among them, the most stable 1,2-dioxetane was synthesized by Wieringa in 1972 
from adamantylidenadamantane using sensitized oxygenation.20 It has been well accepted that 
bulky structures such as adamantine are important to stabilize the highly restrained dioxetane by 
preventing the elongation of O−O and C−C bonds.21 The thermal decomposition energy of this 
sterically stabilized structure is 37 kcal/mol and its half-life at 20 ºC is more than 20 years.22 
Initial applications of these 1,2-dioxetanes were mainly limited by their thermal 
decompositions.23  
A great number of methods for the preparation of 1,2-dioxetane have been reported over 
the last five decades. The most widely used methods generally fall into two categories, 
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cyclization of halogen hydroperoxides by base or silver ion18 and oxidation of alkenes with 
singlet oxygen (Scheme 1-2). The singlet oxygen can be generated by either photosensitizer such 
as Rose bengal or methylene blue with light irradiation or a phosphite ozonide which can be 
prepared by bubbling ozone into phosphite solution at –78 °C.24  
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Scheme 1-2. Some examples of the synthetic routines for 1,2-dioxetane. 
  
1.2 Mechanistic insight of the chemiluminescent decomposition of 1,2-dioxetanes 
1.2.1 Thermal decomposition 
             The thermal fragmentation of a 1,2-dioxetane proceeds through a cycloelimination 
process by generating two ketone compounds, a fragment of which is in its excited state.25 The 
mechanism of the unimolecular and uncatalyzed decomposition of 1,2-dioxetanes has been 
thoroughly studied and three different mechanistic schemes have been proposed based on 
experiments and theoretical simulations.26,27 They are the concerted, the biradical, and the 
merged mechanism (Scheme 1-3). The O−O and C−C bonds break at the same time for the 
concerted process, which was proposed by McCapra and Turro.28,29 The biradical mechanism 
suggested by O’Neal and Richardson starts with the cleavage of the O−O bond as the rate 
limiting step to form a dioxy biradical as the real intermediate, followed by the subsequent C−C-
bond cleavage, eventually leading to the formation of two carbonyl fragments.30,31 Even though 
the biradical mechanism has been tested to be more compatible with most experimental data in 
this process32 and fits the ab initio calculation results,33 the concerted mechanism was claimed to 
be more accurate to account for the excited state formation and the ratio of singlet and triplet 
quantum yields in this transformation.27,34 Based on calculations, a merged mechanism has been 
proposed recently, where O−O and C−C bonds don’t cleave in a simultaneous fashion.35,36 The 
Br2, H2O2















  8 
O–O bond breaks first but the difference is small enough that no biradical intermediate forms. 
The uncatalyzed thermal decomposition of 1,2-dioxetanes leads to efficient formation of triplet 




Scheme 1-3. Proposed mechanisms for unimolecular decomposition of 1,2-dioxetane, (a) the 
concerted mechanism, and (b) the biradical mechanism.25 
 
1.2.2 Catalyzed decomposition  
Catalyzed decomposition is different from thermal uncatalyzed fragmentation which 
starts by promoting the electron transfer to the dioxetane either by an intermolecular activator 
(ACT) or an intramolecular electron rich substituent. The singlet product is dominant for 
catalyzed decomposition and as a result, the chemiluminescence emission is much more 
efficient.38 Although the detailed mechanism of catalyzed decomposition is not perfectly 
understood, one that is well accepted is chemically initiated electron exchange luminescence 
(CIEEL) mechanism which was originally proposed by Koo and Schuster.39,40 Wilson and 
McCapra refined this mechanism later by replacing a full one electron with partial charge 
transfer.41 Recently Isobe and coworkers reported charge transfer donor molecule exists together 
with 1,2-dioxetane in a solvent cage.42 The ACT is essential in the intermolecular energy transfer 
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initiate the electron transfer from the ACT to the O−O σ* orbital of the dioxetane, and 
subsequently the O−O and C−C bonds break to generate a carbonyl radical anion and the radical 
cation of the ACT inside the solvent cavity. Then a back-electron transfer process between them 
leads to the formation of ACT in its electronically excited state. Upon relaxation to its ground 
state, the chemiluminescence emission is released (Scheme 1-4). 
 
 
Scheme 1-4. Chemically initiated electron exchange luminescence (CIEEL) mechanism for 
activator (ACT) catalyzed intermolecular decomposition of 1,2-dioxetane. 
 
Baader and coworkers reported that introducing electron donating groups to the dioxetane 
can significantly increase the chemiluminescent intensity,21 which was further confirmed by 
Schaap and Gagnon using a phenol substituted dioxetane, 1-(4-hydroxyphenyl)-6-phenyl-2,5,7,8-
tetraoxobicyclo [4.2.0]octane (HPTBO).43 Chemiluminescence emission was greatly enhanced 
by removing the phenolic proton, and light can be triggered without the addition of ACT. It is 
believed that the charge transfer from an intramolecular electron rich group, such as a phenolate, 
initiates the cleavage of the O−O and C−C bonds of the four-membered dioxetane ring. A back-
electron transfer step then produces the excited species which relaxes with the emission of light. 
The energy of this excited intermediate can be transferred to other energy acceptors, such as 
fluorescent dye, which results in a fluorescent emission. The detailed process has been outlined 
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recent advances in the mechanistic studies of 1,2 dioxetanes, the exact mechanism of light 
emission has not yet been elucidated.  
 
 
Scheme 1-5. CIEEL mechanism for the catalyzed intramolecular decomposition of 
spiroadamantane-1,2-dioxetane. 
 
Based on this discovery, coupled with the stable effect of a bulky adamantane group, 
Schaap and coworkers developed some 1,2-dioxetane derivatives containing masked phenolate 
groups (Scheme 1-6).44,45 Efficient chemiluminescence can be triggered by the deprotection of 
the phenolate masking group by the action of specific chemical or enzymatic deprotecting 
agents. A simple example is chemiluminescence that can be produced by using tetrabutyl 
ammonium fluoride to de-mask the tert-butylsilyl from a phenolate. Other masking groups such 
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Scheme 1-6. 1,2-Dioxetane derivatives containing masked phenolate groups (MG = masking 
group). 
 
1.3 Triggered chemiluminescence from 1,2-dioxetanes 
Schaap and coworkers pioneered this area with the first report of chemical and enzymatic 
triggering chemiluminescence from 1,2-dioxetanes in 1987.44,45 Tremendous progress and 
numerous applications in this field have occurred since then. The intrinsic low background signal 
of this imaging modality in combination with high specificity of the target recognition unit 
catered for a specific target have dramatically expanded the use of chemiluminescence for 
analytical and biomedical programs.  
These strategies of chemically or enzymatically46 deprotecting the phenolate forms the 
basis of the notion that by changing substituents on phenoxy-dioxetanes, efficient 
chemiluminescence can be triggered by target molecules through desired transformations with 
high specificity. It also laid the foundation for the preparation of target-directed 
chemiluminescent probes for bio-imaging. Furthermore, a 1,2-dioxetane bearing a meta-
substituent on phenoxy-dioxetanes gives better chemiluminescent efficiency.47,48 Even though 
triggered 1,2-dioxetane seems an ideal platform for the design and preparation of 
chemiluminescent probes for in vivo imaging, the low chemiluminescent quantum yield of this 
scaffold under physiological conditions has largely hindered its further biological applications. 
Scientists have invested considerable efforts in the development of better scaffolds and systems 
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apply this scaffold for biological applications was realized by the incorporation of a polymeric 
enhancer solution to improve chemiluminescent intensity by creating a hydrophobic pocket to 
reduce the water initiated quenching effect and a fluorescent dye to red-shift luminescence 
emission.  
Shabat and coworkers recently reported several methods to increase the 
chemiluminescent quantum yield49 and red-shift the scaffold emission50 using intramolecular 
energy transfer and direct chemical modifications of the core structure. Their methods centered 
around the introduction of electron withdrawing groups, efficient fluorophores, and direct NIR 
dye conjugations to provide new ways to increase the chemiluminescence quantum yields and 
prepare bright chemiluminescent agents for biological applications without any other additives. 
With the introduction of an electron withdrawing group at the ortho-position to the reactive site, 
the chemiluminescent intensity was significantly increased. Particularly, with the ortho-
acrylonitrile substituent, they increased the chemiluminescent quantum yield by 3000-fold in 
aqueous solution and the chemiluminescence emission reached approximately the same level 
compared with the enhancer incorporated systems. Based on these structural advancements, 
several in vivo or cellular reaction-based chemiluminescent probes have been reported, including 
b-galactosidase, H2O2,49 Cathepsin B,51 and peroxynitrite52 (Scheme 1-7). With these 
improvements and further structural and system optimizations, we are optimistic about the future 
application of this imaging modality.  
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Scheme 1-7. Some examples of reaction-based chemiluminescent agents.  
 
1.5 Reaction-based probes for interrogating biological species  
 
Living systems are a complex collection of an enormous variety of biomolecules 
including organic compounds, inorganic species, and polymers that together maintain a dynamic 
environment with a great number of transformations. An overarching goal in biology is to 
decipher detailed functions of each compound in living systems. To this end, scientists have 
proposed many specific methods to monitor the behavior of biomolecules. Among them, optical 
imaging methods have received tremendous attention during the last three decades, which 
provide powerful tools to interrogate biological systems with high spatiotemporal resolution. 
Molecular imaging techniques have tremendously advanced our understanding of the dynamics 
of biomolecules in a complex environment. Reaction-based probes, which can be defined as 
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photochemical change have stimulated an explosion of biological discoveries over the past three 
decades. Roger Tsien and coworkers pioneered this field by the development of reaction-based 
probes for metal cations especially calcium cation (Ca2+). Their design strategy was to link a 
Ca2+ chelator, 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid, to a fluorophore which 
displayed a wavelength change upon Ca2+ binding, enabling a ratiometric readout.53 A lot of 
photophysical processes have been explored to construct these imaging agents, such as 
fluorescence resonance energy transfer (FRET)54, intramolecular charge transfer (ICT)55 and 
photo-induced electron transfer.56 Therefore, a considerable amount of fluorescent on-off and 
ratiometric chemosensors for pH and metal cations, such as zinc, iron and copper have been 
reported since then. Later, a myriad of organic transformations has been applied for the 
development of reaction-based probes. Nagano and co-workers used cycloaddition for singlet 
oxygen (1O2) detection,57 and the same group discovered that aromatic vicinal diamines can react 
with nitric oxide (NO) in the presence of oxygen, resulting the development of 
diaminofluoresceins.58 Chang and coworkers utilized H2S mediated azide reduction for H2S 
detection59 and they also pioneered H2O2 imaging using oxidative cleavage of boronic ester.60 
Reaction-based probes have also been used to monitor enzymes such as galactosidase,61 and 
reductive enzymes62 (Scheme 1-8). These reaction-based probes help us better understanding the 
dynamics of these species in living systems. Significantly, the existence and dynamics of some 
transient species, such as reactive sulfur, oxygen, and nitrogen (RSON) species have been 
visualized for the first time, which helps us better understand their detailed productions, 
distributions and functions in health and pathological state. Trying to reveal more biological 
details of these reactive species motivates chemists to make state-of-the-art imaging probes with 
high sensitivity and specificity. There are several stringent criteria that need to be fulfilled for 
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reaction-based probe development. (1) The reaction should be specific and selective between 
probe and target, which means that the probe should respond selectively to its intended target in 
a complex biological system without interference from any other species. (2) Reasonable 
reaction kinetics under physiological conditions between probe and target is required. (3) The 
probe and product produced from this reaction have to be biocompatible. Relying on the specific 
reactivity between an organic functionality and an analyte of interest and various methods to tune 
chemical reactivity, many probes have been used to interrogate the biological details of 
biomolecules, which as a result has significantly advanced biology research and also laid the 
foundation for subfields of chemical biology research.  
  16 
  
Scheme 1-8. Examples of some reaction-based probes for (a) Ca2+, (b) pH, (c) NO, (d) 1O2, (e) 
H2S, (f) H2O2, (g) galactosidase, and (h) quinone oxidoreductase-1. 
 
1.6 In vivo imaging  
Seeing is believing. Optical imaging methods have greatly enabled us to “see” the 
biological processes at the cellular and molecular level. Among them, magnetic resonance 
imaging (MRI), positron emission tomography (PET), fluorescence and bioluminescence63 are 
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1.6.1. PET/MRI 
PET is an imaging technique that detects the signal from radiotracer to observe metabolic 
processes in the body.64 MRI uses magnetic resonance techniques to form anatomic images.65 
Both modalities have been used in clinical settings for diagnostic purposes. PET imaging gives 
high sensitivity and molecular information and MRI provides high spatial and contrast resolution 
information. In a clinical setting, these two methods have been combined in a frequent fashion to 
improve diagnostic performance.66 These two imaging modalities are primarily used for 
revealing anatomical, physiological and metabolic parameters, and are not quite suitable as 
laboratory tools to explore cellular or molecular details. Furthermore, despite their great potential 
in clinical studies, these two methods normally require expensive instrumentations and highly 
trained personnels, which limits their access to basic research programs. 
 
1.6.2 Fluorescence 
With the discovery and development of green fluorescent protein (GFP) from jellyfish, 
Aequoria Victoria.,67 fluorescence imaging has significantly contributed to the advancement of 
biological research. GFP emits at a wavelength of ~510 nm when irradiated at ~470 nm. GFP has 
been introduced into many systems as a fusion tag to study biological processes such as gene 
expression and protein localization and movement.68 The important contribution of GFP to 
biological study was recognized by the 2008 Nobel Prize in chemistry. Small fluorescent dyes, 
such as fluorescein and rhodamine have also facilitated the study of biological systems. Target-
specific fluorescent probes have enabled us to monitor the detailed biological processes of single 
species with high specificity and resolution.69  The general concept behind these fluorescent 
proteins and small fluorophores are that these molecules are emissive upon irradiation at specific 
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wavelength. The imaging can be formed by collecting the emission wavelength from these 
molecules or by calculating the ratio at two different wavelengths. Under some circumstances, 
small fluorescent agents are favored compared to GFP because (1) their small size would cause 
small interference in living systems; (2) they are easier to implement without the requirement of 
gene engineering; and (3) they can be easily modified to tune the wavelength, sensitivity and 
selectivity. Tsien, Nagano, Chang and numerous other labs have greatly advanced in vivo 
reaction-based fluorescence imaging, resulting in a great amount of state-of-the-art reaction-
based fluorescent probes for reactive species, metal ions, and enzymes. Some of these probes 
have been successfully applied for elucidating new biological details in vivo. These reaction-
based fluorescent agents have become indispensable tools in modern biology because they 
provide dynamic information regarding the quantity and localization of an analyte of interest. In 
order to translate this imaging modality for deeper tissue imaging, there has been an explosion of 
reporters of NIR fluorescent probes due to the beneficial effect of red light. NIR fluorophores 
normally emit above 650 nm. The light in this range is less scattered and less absorbed by tissue 
and biomolecules. With less light scattering and autofluorescence, it can be applied for deep 
tissue imaging (> 0.5 cm). NIR fluorescence image-guided surgery is becoming a popular area.70 
Although fluorescence imaging has revolutionized basic research and the NIR fluorescence 
imaging has increased tissue penetration, signal-to-noise ratios and decreased the light scattering 
and autofluorescence, they unfortunately suffer some disadvantages associated with the 
excitation which still generates light scattering, and phototoxicity. Furthermore, it requires 
researchers to know when and where to shine light first, which makes it challenging to explore 
unknown biological processes. 
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1.7 Research objectives 
This dissertation aims to solve the problems associated with current imaging modalities 
and establish chemiluminescence as a versatile imaging modality for in vivo study. Our approach 
involves the design and synthesis of reaction-based chemiluminescent probes for defined 
analytes. The light generated directly from chemical reactions offers some unique advantages, 
such as low background emission and reduced phototoxicity. We have reported CHS-3 for H2S, 
HyCL-2 for hypoxia and both of them demonstrate great potential for in vivo applications. 
Furthermore, CHS-3 is the first demonstration of using chemiluminescence for imaging analytes 
in wild-type animals in this field. Recently we have reported a ONOO– probe PNCL using a 
selective oxidative decarbonylation reaction. PNCL has been successfully applied for detecting 
endogenously produced ONOO– in enhancer free conditions. Overall, the goal is to demonstrate 
that chemiluminescence holds great potential for in vivo imaging and we are confident that with 
the continuous improvement of this technique, it will be widely applied for visualization of 
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CHAPTER 2 
CHEMILUMINESCENT PROBES FOR IMAGING H2S IN LIVING ANIMALS 
 
2.1 Introduction 
  Hydrogen sulfide (H2S) with the odor of rotten egg has long been viewed as a toxic 
gas to biological systems.1 However, accumulating evidence revealed that in addition to 
being a toxic geological and environmental pollutant, H2S is also produced and 
distributed in mammalian systems in a controlled fashion,2 indicating its underestimated 
but broad biological functions in mammalian physiology and pathology.3 H2S is a weak 
acid with pKa1 and pKa2 of 6.9 and >12 and HS– is the main species at physiological 
conditions (pH=7.4).4 The two electron redox potential of H2S is +0.17 V at pH 7.0 
coupled to a standard hydrogen electrode (SHE),.5 The general realization of the 
biological functions of H2S started in the 1990s, when Abe and Kimura reported that H2S 
functions as a neuromodulator in hippocampal long-term potentiation.6 Since then, H2S 
received tremendous attention in scientific research fields. However, the biological 
concentration of H2S remains controversial and has over a 105-fold range with reported 
studies.7 H2S is mainly produced by two general pathways in physiological conditions. 
One involves non-enzymatic processes where H2S can be generated from sulfur 
containing compounds including glucose, glutathione (GSH), inorganic and organic 
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polysulfides.8 The other involves enzymatic processes and three enzymes, cystathionine 
gamma lyase (CSE),9 cystathionine beta synthase (CBS)10 and 3-mercaptopyruvate 
sulfurtransferase (3-MST)11 are involved in the generation of endogenous H2S by utilizing 
sulfur containing biomolecules such as cysteine and homocysteine (Hcy) (Scheme 2-
1).10,12 These enzymes have been reported to be organ specific, and H2S has been found in 
most tissues of living systems, including vasculature,13 brain,6,14 lungs,15 liver,9 and 
pancreas,16 revealing its widespread physiological roles in living systems. For example, it 
can be produced in neural systems to mediate neural communication, and it also plays 
active role in the cardiovascular system and redox regulation (Figure 2-1). However, 
misregulated H2S production and distribution are associated with various diseases, such 
as hypertension,17 diabetes,18 Down’s syndrome,19 Alzheimer’s disease20 and cancers.21 
Considering the multifaceted biological roles of H2S and physiological implications of 
H2S, new biocompatible tools for detection and monitoring the production, trafficking, 
and consumption of this gasotransmitter in living cells and animals are needed. 
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Scheme 2-1. Enzymatic pathways for H2S generation.  
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  Traditional methods for H2S detection, including the methylene blue assay, high 
performance liquid chromatography, mass spectrometry, gas chromatography, and 
electrochemical methods are all unable to provide real time measurement of  H2S in intact 
living organisms with high sensitivity.22 Over the past decade, reaction-based fluorescent 
probes for H2S detection have received tremendous attention, which enables us to detect 
H2S in live cells with higher spatiotemporal resolution and greater selectivity.23 These 
reaction-based methods make use of the chemical reactivity of H2S, including 
nucleophilicity,24 metal precipitation25 and reductivity. 26 However, the drawbacks of 
fluorescence imaging associated with autofluorescence, light scattering, phototoxicity, 
and probe kinetics impedes its application for study H2S in living animals.27 A 
chemiluminescent platform could provide a unique solution to these problems. Direct 
light production from a chemical reaction provides this imaging modality with some 
unique advantages. In order to expand the toolbox for reaction-based chemiluminescent 
probes for H2S28 and overcome the limitations of current H2S detection methods, we 
developed three chemiluminescent probes for rapid and selective imaging of H2S in living 
animals. 
  The chemiluminescence emission can be initiated by the encounter of the probe 
and the analyte of interest.29 Monitoring the generation and intensity of the 
chemiluminescence emission enables us to determine the presence and concentration of 
the target molecule and provides a highly sensitive and selective readout. Unlike 
fluorescent detection methods, no external light excitation is needed for triggering 
chemiluminescence emission, which can drastically reduce background from 
autofluorescence and light scattering. Bioluminescence, a subtype of chemiluminescence, 
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has received widespread attention for its potential value for in vivo imaging. Although a 
number of bioluminescent probes for living animal imaging have been reported to date,30 
their potential applications are largely hindered by the need of enzymatic additive or 
genetic modification.31 
  While chemiluminescent methods have been extensively applied for 
immunoassays,32 enzymatic analyte detection,33 reaction-based chemiluminescent probes 
for in vivo imaging remain rare. Herein, we report three reaction-based chemiluminescent 
H2S probes, CHS-1, CHS-2, and CHS-3 based on spiroadamantane 1,2-dioxetane. The 
design principle, synthetic strategies, chemiluminescent response and selectivity to H2S, 
cellular H2S detection, and living animal imaging will be outlined in this chapter. 
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Scheme 2-3. Spiroadamantane 1,2-dioxetanes for chemiluminescent H2S detection at neutral pH. 
 
2.2 Results and discussion 
2.2.1 Design principle and synthesis of CHS-1, CHS-2, and CHS-3 
  CHS probes were designed by linking a chemiluminescent scaffold, 
spiroadamatane 1,2-dioxetane with phenyl azide through a carbonate linkage.34 H2S first 
reduces the azide. The mechanism of this H2S mediated azide reduction has been reported 
by the Pluth group. This reaction is first-order for both reactants and two equivalents of 
HS– are needed (Scheme 2-2).35 After reduction, a self-immolative carbonate cleavage 
yields the free phenolate. Chemiluminescence emission can be triggered upon 
decomposition of this phenolate through CIEEL mechanism (Scheme 2-3).36 This newly 
generated chemiluminescence emission can be detected directly or by donating its energy 
to other molecules such as quantum dots or fluorescent dyes.37 Emerald II Enhancer, 
containing a cationic polymer and a dye, was adapted in our study as an energy acceptor, 
which not only red shifts the luminescence emission but also increase luminescent 
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Scheme 2-4. Syntheses of CHS-1, CHS-2, and CHS-3. 
 
  We achieved a modular synthetic route to access the probes CHS-1, CHS-2 and 
CHS-3 with some optimizations of a literature procedure39 (Scheme 2-4). The synthesis 
started with treating unsubstituted, fluorinated, and chlorinated 3-methoxybenzaldehyde 
derivatives 1a–c with trimethyl orthoformate in the presence of p-toluenesulfonic acid to 
afford acetals 2a–c. These acetals reacted with triethyl phosphite and boron trifluoride 
diethyl etherate to give the diethyl methoxy (3-methoxyphenyl) methyl phosphonates 3a–
c. Then phosphonates 3a-c went through Horner–Wadsworth–Emmons reaction with nBuLi 
and 2-adamantanone to afford enol ethers 4a–c.40 Nucleophilic demethylation using sodium 
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literature procedure, 41 , 42  was coupled to the phenols to afford 7a–c. Finally, a [2+2] 
cycloaddition was conducted by bubbling oxygen through a solution of 7a–c and the 
sensitizer Rose bengal with light irradiation, giving the final chemiluminescent probes 
CHS-1, CHS-2, and CHS-3.  
 
2.2.2 Response and selectivity  
After obtaining these chemiluminescent probes, we started to characterize their 
luminescent responses and sensitivity towards H2S using an F-7000 Hitachi fluorometer. 
Each probe (40 µM) displayed instantaneous light production after treating with H2S in 
the presence of 20% Emerald II Enhancer in 20 mM HEPES buffer (pH 7.4). The 
luminescence emission gradually increased over a time course of 10 minutes in a dose-
dependent manner (Figure 2-2). The light emission could last for more than an hour 
(Figure 2-3). The emission spectra showed two peaks. The major peak centred at 545 nm 
corresponding to the dye in the Emerald II Enhancer, and the small one at 450 nm was 
from the emission of the decomposition of phenolate (Figure 2-1, insets), indicating that 
the luminescence mostly donates to the acceptor. We observed that CHS-1, CHS-2 and 
CHS-3 give 5-fold, 4-fold, and 12-fold luminescence turn-on respectively using 
integrated luminescent intensity under physiologically relevant conditions. No 
background corrections were performed in our study in order to accurately compare the 
luminescent response between probes. The chemiluminescent response towards H2S at pH 
10 was also investigated. CHS-1 displayed the highest chemiluminescence emission, 
resulting in a 7-fold turn-on in 10 minutes (Figure 2-4), while CHS-2 and CHS-3 gave 2-
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fold and 3-fold luminescent turn-on respectively. This experiment demonstrated that pH 
is an important trait in regulating the luminescence emission. 
 
 
Figure 2-2. Time scans of the chemiluminescence emission at 545 nm from (a) 40 µM CHS-1, 
(b) 40 µM CHS-2, or (c) 40 µM CHS-3 and 0, 5, 10, 20, 40, 80, 100, 150, 200 µM Na2S in 20 
mM HEPES buffer (pH 7.4) containing 20% Emerald II Enhancer. Insets are chemiluminescence 
spectra of (a) 40 µM CHS-1, (b) 40 µM CHS-2, and (c) 40 µM CHS-3 and 200 µM Na2S, 
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Figure 2-3. Long time scan of the chemiluminescence emission at 545 nm of 40 µM CHS-3 to 
200 µM H2S in 20 mM HEPES buffer (pH 7.4) containing 20% Emerald II Enhancer. 
 
 
Figure 2-4. Time scans of the chemiluminescence emission at 545 nm from (a) 40 µM 
CHS-1, (b) 40 µM CHS-2, or (c) 40 µM CHS-3 and 0 µM (red) or 200 µM (black) H2S 
in 100 mM glycine buffer (pH 10.02) containing 20% Emerald II Enhancer. 
 
  After demonstrating that CHS probes can sensitively detect H2S at physiologically 
relevant pH, we next tested the selectivity of CHS-1, CHS-2, and CHS-3 for H2S against 
other biologically relevant RSON species. The selectivity test was carried out by treating 
40 µM CHS-1, CHS-2 and CHS-3 with different amount of RSON species in 20 mM 
HEPES buffer (pH 7.4). 5 mM reduced GSH, 1 mM L-cysteine and Hcy, and 200 µM of 
S-nitrosoglutathione, sulfite (SO32–), hydrogen peroxide (H2O2), hypochlorite (OCl–), tert-
butyl hydroperoxide (tBuOOH), nitroxyl (HNO), nitric oxide (NO), and nitrite (NO2–) 
were used for evaluation. None of the other species tested displayed significant increases 
in luminescence intensity over the blank control over a time course of 10 minutes. 
(a) (b) (c) 
  34 
Furthermore, the response to Na2S was also tested in the presence of GSH, L-cysteine, 
and Hcy. No significant chemiluminescent change was observed (Figure 2-5). These 
selectivity data showed that CHS-1, CHS-2, and CHS-3 are capable of detecting H2S 
selectively without interference from completing analytes. 
 
 
Figure 2-5. Chemiluminescent responses of (a) 40 µM CHS-1, (b) 40 µM CHS-2, or (c) 40 µM 
CHS-3 to biologically relevant RSON species in 20 mM HEPES buffer (pH 7.4) containing 20% 
Emerald II Enhancer. Bars represent chemiluminescence emission at 545 nm and 30, 60, 120, 
240, 360, 480 and 600 second after addition of RSON species. Data shown are for 5 mM GSH, 1 
mM cysteine and Hcy, and 200 µM for other RSON species. Legend: (1) Na2S; (2) Na2S, GSH, 
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NO; (9) NaNO2; (10) Na2SO3; (11) H2O2; (12) NaClO; (13) tBuOOH; (14) Blank. Error bars are 
± S.D. 
 
2.2.3 Mechanistic studies of chemiluminescent H2S detection 
In order to gain insight into the structure details regarding the chemiluminescent intensity 
and guide us to prepare better chemiluminescent probes, we started to study the equilibrium of 
phenol/ phenolate using pKa of phenol, 2-fluorophenol, and 2-chlorophenol as an approximation 
due to the difficulty of measuring the pKa of these phenoxy-dioxetanes.43 We integrated 
chemiluminescence emission of CHS-1, CHS-2, and CHS-3 in response to 200 µM Na2S at pH 
7.4 and pH 10 over a time course of 10 min (Figure 2-6a,b). We plotted the integrated 
chemiluminescent intensity against the pKa values of phenol, 2-fluorophenol, and 2-chlorophenol 
(Figure 2-6c,d). We observed that at pH 7.4 the chemiluminescent intensity increased when 
lowering the pKa which corresponds to higher ratio of phenolate to phenol (Figure 2-6c), while 
no direct correlation was observed between pKa and the chemiluminescent intensity at pH 10 
(Figure 2-6d). To further investigate this correlation, we performed a quantum chemical 
calculation by calculating the phenolate structures from CHS-1, CHS-2, and CHS-3 (Tables S2-
1–S2-3). Density functional theory (DFT) at the B3LYP/6-311+G(d,p) level of the theory was 
applied to optimize the geometries, and the charge on each atom was calculated by electrostatic 
potential (ESP) model at the M06/6-311+G(d,p) level of theory. The solvent effect of water was 
modeled by the integral equation formalism polarizable continuum model (IEF-PCM) using 
Gaussian 09 package. The computational calculation results indicated that the charge on the 
phenolic oxygen (O8) determines the chemiluminescent intensity at pH 10 (Figure 2-6f), while 
there was no such correlation at pH 7.4 (Figure 2-6e). This result was further verified by ESP 
charge calculations performed with B3LYP and ωB97XD functions (Figure 2-11). These data 
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indicated that at lower pH, the chemiluminescence emission was determined by the ratio of 
phenolate and phenol consistent with the CIEEL mechanism. However, the negativity of O8 is 
responsible for the chemiluminescent intensity at pH 10, which can be explained by the fact that 
negative charge promotes the electron transfer step of CIEEL.44  
 
 
Figure 2-6. Analysis of chemiluminescent responses. (a)–(b) Bar graphs for the integrated 
chemiluminescence emission over 10 min at (a) pH 7.4 or (b) pH 10 of CHS-1, CHS-2, and 
CHS-3 to 0 µM Na2S (grey bars) and 200 µM Na2S (colored bars). (c)–(d) Plot of the integrated 
chemiluminescence emission over 10 min at (c) pH 7.4 or (d) pH 10 of 200 µM Na2S and 40 µM 
CHS-1 (red), CHS-2 (green) and CHS-3 (blue) versus experimental pKa values of model 
compounds phenol, 2-fluorophenol, and 2-chlorophenol. (e)–(f) Plot of the integrated 
chemiluminescence emission over 10 min at (e) pH 7.4 or (f) pH 10 of 200 µM Na2S and 40 µM 
CHS-1 (red), CHS-2 (green) and CHS-3 (blue) versus the calculated atomic charge on the 
phenolate oxygen (O8). All luminescent measurements were acquired in 20 mM HEPES buffer 
(pH 7.4) or 100 mM glycine buffer (pH 10) containing 20% Emerald II Enhancer. The reported 
values are averages of the integrated emission intensities over 10 min (n = 4–7). Error bars 
represent ± S.D. The ESP atomic charges were calculated at the M06/6-311+G(d,p) level of the 
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were carried out with the IEF-PCM water solvation model using the Gaussian 09 program 
package. (Computational work was conducted by Dr. Tao and coworkers) 
 
2.2.3 Using CHS-3 to detect cellular H2S   
We next applied our probe to detect cellularly generated H2S in human lung 
adenocarcinoma epithelial cells (A549). CHS-3 was chosen to perform cellular H2S detection 
due to its most robust luminescence emission at physiological pH. A549 expresses CSE45 
which can utilize Hcy to produce H2S. Before the cell experiment, we first used CHS-3 to 
detect exogenous H2S using a plate reader by loading a 96 well plate with different 
amounts of H2S (Figure 2-7a). The luminescent intensity increased with increasing 
concentration of H2S, demonstrating that CHS-3 is capable of sensitively detecting Na2S 
in a multi-well plate reader format. The detection limit was estimated to be 5.4 µM.  
A549 cells were first incubated with Hcy, followed by the addition of CHS-3 and 
Emerald II Enhancer, and then the plate was subjected to plate reader test. The cells 
treated with Hcy resulted in ~10% luminescent increase (n = 12, p = 0.044) compared 
with DI-H2O treated control (Figure 2-7b). An enzyme inhibition experiment was also 
conducted by treating the cell with DL-propargylglycine (PAG), a CSE inhibitor, 20 
minutes prior to Hcy addition. A slightly decreased luminescence emission was observed, 
confirming that CHS-3 can be applied for detecting cellularly generated H2S. 
 
  38 
 
Figure 2-7. Detection of cellular H2S using a multi-well plate reader. (a) Luminescent responses 
of 40 µM CHS-3 and 0, 25, 50, 100, and 200 µM Na2S in 20 mM HEPES buffer (pH 7.4) 
containing 20% Emerald II Enhancer. (b) A549 cells were treated with a vehicle control (DI-
H2O), 200 µM Hcy, or 200 µM Hcy after being pre-treated with 200 µM PAG (Hcy + PAG) for 
20 min. 20 min after incubating with Hcy or vehicle, the cells were washed and treated with 40 
µM CHS-3 and 125 µL Emerald II Enhancer. The reported values represent the average 
luminescent intensity of replicate experiments (n = 12, p = 0.044). Error bars represent ± S.E.M. 
 
2.2.4 In vivo imaging of H2S using CHS-3 
After demonstrating that CHS-3 is capable of detecting cellular H2S, we started to 
evaluate the ability of CHS-3 to image H2S in living animals using an IVIS Spectrum. 
We first applied CHS-3 to image H2S at physiological pH using an opaque 96-well plate 
by loading with different amount of Na2S in 20 mM HEPES buffer (pH 7.4) containing 
20% Emerald II Enhancer. A dose dependent luminescent response was observed (Figure 
2-8a) with good linearity in the range of 0–200 µM of H2S (Figure 2-8b). After knowing 
CHS-3 is capable of sensitive and accurate imaging of H2S by IVIS Spectrum, we next 
determined if light production from CHS-3 was sufficient to be observed through 
mammalian tissue in a mouse carcass model. CHS-3 was injected into the peritoneal 
cavity of the sacrificed SCID/BALB-C mice without H2S (Figure 2-9a,b) as a vehicle 
control (DI-H2O) or with 0.4 µmol H2S (Figure 2-9c,d). The carcass injected with H2S 
showed a clear and significant luminescent increase (Figure 2-9e). This important 
experiment demonstrated that luminescence generated from CHS-3 was sufficient enough to 





















L p = 0.044 
n.s. 
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penetrate mammalian tissue. Finally, we proceeded to apply CHS-3 to image H2S in living 
animals. A mixture of 0.08 µmol CHS-3 and 0.4 µmol Na2S in HEPES buffer containing 20% 
Emerald II Enhancer was administrated via i.p. injection into the peritoneal cavity of C6 brown 
mice (Figure 2-10a). For a vehicle control, Na2S was replaced with same volume of DI-H2O 
(Figure 2-10b). Images were acquired 30 second after injecting. The mice treated with Na2S 
displayed ~4-fold luminescent increase compared with vehicle control (Figure 2-10c), 
demonstrating that CHS-3 is capable of detecting H2S in living mice. 
 
 
Figure 2-8. Imaging H2S using CHS-3. (a) Images 30 sec after adding 40 µM CHS-3 to 0, 25, 
50, 100, and 200 µM Na2S in 20 mM HEPES buffer (pH 7.4) containing 20% Emerald II 
Enhancer (n = 3). (b) Plot of total photon flux versus H2S concentration for the experiments 
described in (a). 
 
  40 
 
Figure 2-9. Imaging H2S in SCID/BALB-C mouse carcasses using CHS-3. Images were 
obtained 30 seconds after administering an i.p. injection of 0.08 µmol CHS-3 and (a–b) 
vehicle control (DI-H2O) or (c–d) 0.4 µmol Na2S in 100 µL 20 mM HEPES at pH 7.4 
containing 20% Emerald II Enhancer. (e) Quantification of the total photon flux from 
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Figure 2-10. (a)–(b) Images of living C6 brown mice 30 second after administering i.p. 
injections of 0.08 µmol CHS-3 (and (a) vehicle control (DI-H2O) or (b) 0.4 µmol Na2S in 100 
µL 20 mM HEPES buffer (pH 7.4) containing 20% Emerald II Enhancer. (c) Quantification of 
the total photon flux from three replicates of the experiments described in (a) and (b). Statistical 




  Three reaction-based 1,2-dioxetane chemiluminescent H2S probes, CHS-1, CHS-
2, and CHS-3 have been designed and synthesized and all of them displayed instant light 
production when reacting with H2S at physiological pH with good sensitivity and 
selectivity. These reagents have been applied for H2S detection in vitro via 
spectrophotometers, multi-well plate readers, and IVIS Spectrum instruments. By 
collaborating with Dr. Tao, we have developed a general platform for the prediction of 
the performance of spiroadamantane stabilized phenoxy-dioxetane probes based on the 
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has been successfully applied for cellular H2S detection and has been demonstrated to be 
capable of imaging H2S in living animals. 
 
2.4 Experimental section 
2.4.1 Synthetic procedures 
All reactions were performed in dried glassware under an atmosphere of dry N2. Silica gel P60 
(SiliCycle) was used for column chromatography and SiliCycle 60 F254 silica gel (precoated 
sheets, 0.25 mm thick) was used for analytical thin layer chromatography. Plates were visualized 
by fluorescence quenching under UV light or by staining with iodine. Other reagents were 
purchased from Sigma-Aldrich (St. Louis, MO), Alfa Aesar (Ward Hill, MA), EMD Millipore 
(Billerica, MA), Oakwood Chemical (West Columbia, SC), and Cayman Chemical (Ann Arbor, 
MI) and used without further purification. 1H NMR and 13C NMR spectra for characterization of 
new compounds and monitoring reactions were collected in CDCl3 (Cambridge Isotope 
Laboratories, Cambridge, MA) on a JEOL 500 MHz spectrometer in the Department of 
Chemistry at Southern Methodist University. All chemical shifts are reported in the standard 
notation of parts per million using the peak of residual proton signals of the deuterated solvent as 
an internal reference. Coupling constant units are in Hertz (Hz) Splitting patterns are indicated as 
follows: br, broad; s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of 
doublets; dt, doublet of triplets. High resolution mass spectroscopy was performed on a 
Shimadzu IT-TOF (ESI source) and low resolution mass spectroscopy was performed on a 
Shimadzu LCMS-8050 Triple Quadrupole LCMS (ESI source) or a Shimadzu Matrix Assisted 
Laser Desorption/Ionization MS (MALDI) at the Shimadzu Center for Advanced Analytical 
Chemistry at the University of Texas, Arlington. 
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Diethyl(methoxy(3-methoxyphenyl)methyl)phosphonate (3a). 3-Methoxybenzaldehyde (1.83 
mL, 15.0 mmol, 1.0 equiv), trimethyl orthoformate (1.65 mL, 15.0 mmol, 1.0 equiv) and p-
toluenesulfonic acid (258 mg, 1.50 mmol, 0.10 equiv) were added to a dry round-bottom flask 
and flushed with N2. The reaction contents were dissolved in 6.0 mL of MeOH. The reaction 
proceeded for 24 h at rt, and was then neutralized with NEt3. After neutralization, the crude 
mixture was poured into 30 mL saturated aq NaHCO3. The layers were separated and the 
aqueous layer was washed with an additional 2 x 40 mL EtOAc. The combined organic layers 
were collected and dried over Na2SO4, filtered, and concentrated to yield the crude acetal 2a 
(2.52 g). Compound 2a (1.94 g, 10.7 mmol, 1.0 equiv) was dissolved in 10.0 mL CH2Cl2, and 
triethyl phosphite (1.89 mL, 11.0 mmol, 1.03 equiv) and boron trifluoride etherate (1.38 mL, 
11.0 mmol, 1.03 equiv) were added dropwise at 0 °C. Once all the reagents were added, the 
reaction was heated to 30 °C and allowed to react for 1 h under N2 atmosphere. The reaction was 
quenched with 20 mL saturated aq NaHCO3, extracted with 2 x 30 mL EtOAc, and evaporated 
under reduced pressure. Purification by column chromatography (40%–100% EtOAc/hexanes) 
afforded 3a as a pale yellow oil (2.332 g, 89%). 1H NMR (500 MHz, CDCl3) d 7.26 (t, 1H, J = 
8.0 Hz), 6.97–7.02 (m, 2H), 6.85 (d, 1H, J = 8.0 Hz), 4.47 (d, 1H, J = 15.5 Hz), 3.90–4.13 (m, 
4H), 3.81 (s, 3H), 3.38 (s, 3H), 1.20–1.29 (m, 6H); 13C NMR (125 MHz, CDCl3) d 159.63, 
135.94, 129.31, 120.43, 114.31, 112.96, 80.52, 79.71, 63.10 (d, J = 7.2 Hz), 62.93 (d, J = 7.2 
Hz), 58.76 (d, J = 14.3 Hz), 55.22, 16.40 (d, J = 5.9 Hz), 16.33 (d, J = 5.9 Hz); HRMS calcd for 
C13H21O5P (M+Na+) 311.1019, found 311.1013. 
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Diethyl((4-fluoro-3-methoxyphenyl)(methoxy)methyl)phosphonate (3b). 4-Fluoro-3-
methoxybenzaldehyde (1.0 g, 6.5 mmol, 1.0 equiv), trimethyl orthoformate (0.71 mL, 6.5 mmol, 
1.0 equiv) and p-toluenesulfonic acid (111.9 mg 0.6498 mmol, 0.10 equiv) were dissolved in 4.0 
mL of MeOH. The reaction proceeded for 24 h at rt, and was then neutralized with NEt3. After 
neutralization, the crude mixture was poured into 30 mL saturated aq NaHCO3. The layers were 
separated and the aqueous layer was washed with an additional 2 x 40 mL EtOAc, the combined 
organic layers were collected and dried over Na2SO4, filtered, and concentrated to yield crude 
acetal 2b (1.25 g). Compound 2b (1.25 g, 6.25 mmol, 1.0 equiv) was dissolved in 6.0 mL 
CH2Cl2, and triethyl phosphite (1.10 mL, 6.44 mmol, 1.0 equiv) and boron trifluoride etherate 
(0.80 mL, 6.4 mmol, 1.0 equiv) were added dropwise at 0 °C. Once all the reagents were added, 
the reaction was heated to 30 °C and allowed to react for 1 h under N2 atmosphere. The reaction 
was quenched with 20 mL saturated aq NaHCO3, extracted with 2 x 30 mL EtOAc, and 
evaporated under reduced pressure. Purification by column chromatography (40%–100% 
EtOAc/hexanes) afforded 3b as a yellow oil (1.247 g, 66%). 1H NMR (500 MHz, CDCl3) d 6.92 
(dt, 1H, J = 8.6, 2.3 Hz), 6.83 (dd, 1H, J = 10.9, 2.3 Hz), 6.71–6.75 (m, 1H), 4.26 (d, 1H, J = 
15.5 Hz), 3.80–3.91 (m, 4H), 3.68 (s, 3H), 3.17 (s, 3H), 0.95–1.10 (m, 6H); 13C NMR (125 MHz, 
CDCl3) 152.58, 150.65, 147.02 (d, J = 10.7 Hz), 130.20, 119.90 (d, J = 7.2 Hz), 114.95 (d, J = 
19.1 Hz), 112.11, 79.84, 78.49, 62.41 (d, J = 7.2 Hz), 62.18 (d, J = 7.2 Hz), 58.32 (d, J = 14.3 
Hz), 55.36, 15.70 (d, J = 5.9 Hz), 15.64 (d, J = 5.9 Hz); HRMS calcd for C13H20FO5P (M+Na+) 
329.0925, found 329.0931. 
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Diethyl((4-chloro-3-methoxyphenyl)(methoxy)methyl)phosphonate (3c). 4-Chloro-3-
methoxybenzaldehyde (400 mg, 2.34 mmol, 1.0 equiv), trimethyl orthoformate (256 µL, 2.34 
mmol, 1.0 equiv) and p-toluenesulfonic acid (40.4 mg 0.234 mmol, 0.10 equiv) were added to a 
dry flask and flushed with N2. The reaction contents were dissolved in 1.5 mL of MeOH. The 
reaction proceeded for 24 h at rt, and was then neutralized with NEt3. After neutralization, the 
crude mixture was poured into 20 mL saturated aq NaHCO3. The layers were separated and the 
aqueous layer was washed with an additional 2 x 30 mL EtOAc, the combined organic layers 
were collected and dried over Na2SO4, filtered, and concentrated to yield crude acetal 2c (474 
mg). Compound 2c (474 mg, 2.19 mmol, 1.0 equiv) was dissolved in 2.0 mL CH2Cl2, and 
triethyl phosphite (0.39 mg, 2.3 mmol, 1.0 equiv) and boron trifluoride etherate (0.28 mL, 2.3 
mmol, 1.0 equiv) were added dropwise at 0 °C. Once reagents were added, the reaction was 
heated to 30 °C and allowed to react for 1 h under N2 atmosphere. The reaction was quenched 
with 20 mL saturated aq NaHCO3, extracted with 2 x 30 mL EtOAc, and evaporated under 
reduced pressure. Purification by column chromatography (40%–100% EtOAc/hexanes) afforded 
3c as a pale yellow oil (598 mg, 83%). 1H NMR (500 MHz, CDCl3) d 7.23 (d, 1H, J = 8.1 Hz), 
6.98 (t, 1H, J = 2.0 Hz), 6.83 (dt, 1H, J = 6.3, 2.0 Hz), 4.37 (d, 1H, J = 16.1 Hz), 3.86–4.00 (m, 
4H), 3.81 (s, 3H), 3.29 (s, 3H), 1.11–1.26 (m, 6H); 13C NMR (125 MHz, CDCl3) d 154.82, 
134.40, 129.72, 122.29, 120.74, 111.12, 80.44, 79.43, 63.05 (d, J = 10.7 Hz), 62.81 (d, J = 10.7 
Hz), 58.65 (d, J = 14.3 Hz), 55.97, 16.26 (d, J = 5.9 Hz), 16.18 (d, J = 5.9 Hz); HRMS calcd for 
C13H20ClO5P (M+Na+) 345.0629, found 345.0624. 
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(1r,3r,5R,7S)-2-(methoxy(3-methoxyphenyl)methylene)adamantane (4a). Compound 3a 
(1.27 g, 4.47 mmol, 1.0 equiv) and 2-adamantanone (939 mg, 6.25 mmol, 1.4 equiv) were 
dissolved separately in 15 mL and 8 mL anhydrous THF under N2 atmosphere and cooled to –
78 °C by mixing dry ice with acetone. n-Butyl lithium (3.91 mL, 6.25 mmol, 1.4 equiv) was then 
added dropwise to the solution of compound 3a at –78 °C to form the phosphonate carbanion. 
After 5 min, the 2-adamantanone solution was slowly added. The reaction was slowly warmed to 
rt and heated to 35 °C for 2 h and then refluxed for 1 h. After the reaction mixture was cooled to 
rt, it was quenched with 20 mL saturated aq NH4Cl. The mixture was then extracted with 2 x 30 
mL EtOAc and evaporated under reduced pressure. Purification by column chromatography 
(1:20 EtOAc/hexanes) delivered 4a as a colorless oil (1.2482 g, 85%). 1H NMR (500 MHz, 
CDCl3) d 7.25 (t, 1H, J = 8.0 Hz), 6.89–6.92 (m, 2H), 6.83 (dd, 1H, J = 8.0, 3.0 Hz), 3.81 (s, 
3H), 3.31 (s, 3H), 3.27 (s, 1H), 2.66 (s, 1H), 1.71–1.98 (m, 12H); 13C NMR (125 MHz, CDCl3) d 
159.45, 143.45, 136.95, 131.74, 128.96, 122.05, 114.74, 113.07, 57.82, 55.27, 39.30, 39.16, 
37.29, 32.34, 30.29, 28.42; HRMS calcd for C19H24O2 (M+H+) 285.1849, found 285.1853. 
 
(1r,3r,5R,7S)-2-((4-fluoro-3-methoxyphenyl)(methoxy)methylene)adamantane (4b). 
Compound 3b (1.17 g, 3.87 mmol, 1.0 equiv) and 2-adamantanone (730 mg, 4.86 mmol, 1.3 
equiv) were dissolved separately in 13 mL and 6 mL anhydrous THF under N2 atmosphere and 
cooled to –78 °C by mixing dry ice and acetone. n-Butyl lithium (3.0 mL, 4.86 mmol, 1.3 equiv) 
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was then added dropwise to the solution of compound 3b at –78 °C to form the phosphonate 
carbanion. After 5 min, the 2-adamantanone solution was slowly added. The reaction was slowly 
warmed to rt and heated to 35 °C for 2 h and then refluxed for 1 h. After the reaction mixture was 
cooled to rt, the reaction mixture was quenched with 20 mL saturated aq NH4Cl. The mixture 
was then extracted with 2 x 30 mL EtOAc and evaporated under reduced pressure. Purification 
by column chromatography (1:20 EtOAc/hexanes) delivered 4b as a colorless oil (1.12 g, 85%). 
1H NMR (500 MHz, CDCl3) d 6.99–7.03 (m, 1H), 6.94 (dd, 1H, J = 8.0, 2.0 Hz), 6.79–6.82 (m, 
1H), 3.87 (s, 3H), 3.29 (s, 3H), 3.23 (s, 1H), 2.60 (s, 1H), 1.58–1.97 (m, 12H); 13C NMR (125 
MHz, CDCl3) d 152.58, 150.62, 147.18 (d, J = 10.7 Hz), 142.81, 131.93, 122.12 (d, J = 7.2 Hz), 
115.40 (d, J = 19.1 Hz), 114.22, 57.79, 56.26, 39.24, 39.11, 37.23, 32.38, 30.30, 28.36; HRMS 
calcd for C19H23ClO2 (M+H+) 303.1755, found 303.1762. 
 
(1r,3r,5R,7S)-2-((4-chloro-3-methoxyphenyl)(methoxy)methylene)adamantane (4c). 
Compound 3c (365 mg, 1.13 mmol, 1.0 equiv) and 2-adamantanone (215 mg, 1.43 mmol, 1.3 
equiv) were dissolved separately in 4 mL and 2 mL anhydrous THF under N2 atmosphere and 
cooled to –78 °C by mixing dry ice and acetone. n-Butyl lithium (0.89 mL, 1.4 mmol, 1.3 equiv) 
was then added dropwise to the solution of compound 3c at –78 °C to form the phosphonate 
carbanion. After 5 min reaction, the 2-adamantanone solution was slowly added. The reaction 
was slowly warmed to rt and heated to 35 °C for 2 h and then refluxed for 1 h. After the reaction 
mixture was cooled to rt, it was quenched with 10 mL saturated aq NH4Cl. The mixture was then 
extracted with 2 x 20 mL EtOAc and evaporated under reduced pressure. Purification by column 
chromatography (1:20 EtOAc/hexanes) delivered 4c as a colorless oil (294 mg, 78%). 1H NMR 
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(500 MHz, CDCl3) d 7.30 (d, 1H, J = 8.0 Hz), 6.91 (d, 1H, J = 1.8 Hz), 6.83 (dd, 1H, J = 8.0, 1.8 
Hz), 3.89 (s, 3H), 3.30 (s, 3H), 3.24 (s, 1H), 2.62 (s, 1H), 1.58–1.97 (m, 12H); 13C NMR (125 
MHz, CDCl3) d 154.84, 142.77, 135.44, 132.56, 129.62, 122.54, 121.41, 112.82, 57.90, 56.16, 
39.24, 39.11, 37.21, 32.43, 30.35, 28.34; HRMS calcd for C19H23ClO2 (M+H+) 319.1459, found 
319.1461. 
 
3-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)phenol (5a). Sodium ethane thiolate 
(769 g, 9.14 mmol, 2.5 equiv) and cesium carbonate (2.98 g, 9.14 mmol, 2.5 equiv) were added 
to a dry round bottle flask containing compound 4a (1.04 g, 3.66 mmol, 1.0 equiv) dissolved in 
30 mL anhydrous DMF under N2 atmosphere. After refluxing overnight, the reaction mixture 
was partitioned between EtOAc and NH4Cl, dried over Na2SO4 and evaporated under high 
vacuum to remove residual DMF. Purification by column chromatography (1:15–1:10 
EtOAc/hexanes) afforded 5a as white solid (620.9 mg, 63%). 1H NMR (500 MHz, CDCl3) d 
7.17–7.21 (m, 1H), 6.99 (s, 1H), 6.80–6.94 (m, 3H), 3.35 (s, 3H), 3.23 (s, 1H), 2.67 (s, 1H), 
1.63–1.98 (m, 12H); 13C NMR (125 MHz, CDCl3) d 155.92, 142.62, 136.48, 132.63, 129.11, 
121.70, 115.86, 114.71, 57.73, 39.06, 38.93, 37.03, 32.20, 30.26, 28.16. LRMS (MALDI) calcd 
for C18H22O4 (M+) 270.1620, found 270.1815. 
 
5-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)-2-fluorophenol (5b). Sodium 
ethane thiolate (215 mg, 2.56 mmol, 1.5 equiv) and cesium carbonate (834 g, 2.56 mmol, 1.5 
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equiv) were added to a dry round bottle flask filled with N2 containing compound 4b (516 mg, 
1.71 mmol, 1.0 equiv) dissolved in 10 mL of anhydrous DMF. After refluxing overnight, the 
reaction mixture was partitioned between EtOAc and NH4Cl, dried over Na2SO4 and evaporated 
under high vacuum to remove residual DMF. Purification by column chromatography (1:15 
EtOAc/hexanes) afforded 5b as white solid (323 mg, 62%). 1H NMR (500 MHz, CDCl3) d 7.00–
7.05 (m, 1H), 6.95–6.98 (m, 1H), 6.78–6.82 (m, 1H), 6.74 (m, 1H), 5.47 (s, 1H), 3.30 (s, 3H), 
3.23 (s, 1H), 2.59 (s, 1H), 1.66–1.96 (m, 12H); 13C NMR (125 MHz, CDCl3) d 156.56, 142.77, 
138.58, 135.43, 132.64, 121.73, 117.53, 115.30, 57.89, 39.16, 39.02, 37.10, 32.18, 30.78, 28.23; 
HRMS calcd for C18H21FO2 (M–H+) 287.1453, found 287.1456. 
 
5-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)-2-chlorophenol (5c). Sodium 
ethane thiolate (204 mg, 2.43 mmol, 2.5 equiv) and cesium carbonate (791 mg, 2.43 mmol, 2.5 
equiv) were added to a dry round bottle flask containing compound 4c (309 mg, 0.971 mmol, 1.0 
equiv) dissolved in 9.0 mL anhydrous DMF under N2 atmosphere. After refluxing overnight, the 
reaction mixture was partitioned between EtOAc and NH4Cl, dried over Na2SO4 and evaporated 
under high vacuum to remove residual DMF. Purification by column chromatography (1:12 
EtOAc/hexanes) afforded 5c as white solid (232 mg, 79%). 1H NMR (500 MHz, CDCl3) d  7.28 
(d, 1H, J = 8.0 Hz), 6.98 (d, 1H, J = 3.5 Hz), 6.83 (dd, 1H, J = 8.0, 3.5 Hz) 5.95 (s, 1H), 3.30 (s, 
3H), 3.22 (s, 1H), 2.62 (s, 1H), 1.55–1.96 (m, 12H); 13C NMR (125 MHz, CDCl3) d 151.12, 
142.18, 135.88, 132.79, 128.57, 122.38, 118.84, 116.97, 57.80, 39.08, 38.94, 37.04, 32.22, 30.21, 
28.17; HRMS calcd for C18H21ClO2 (M–H+) 303.1157, found 303.1150. 
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4-azidobenzyl(2,5-dioxopyrrolidin-1-yl)carbonate (6). N,N’-Disuccinimidyl carbonate (830 
mg, 3.25 mmol, 1.5 equiv) was added to a solution of  4-azidobenzyl alcohol (323 mg, 2.16 
mmol, 1.0 equiv) in 5.0 mL CH2Cl2, followed directly by the addition of NEt3 (0.91 mL, 6.5 
mmol, 3.0 equiv). The reaction was stirred for 4 h at rt. The reaction was quenched with 20 mL 1 
M NaHCO3, extracted with 2 x 30 mL EtOAc, washed with 10 mL brine, dried over Na2SO4, 
filtered, and concentrated to yield 6 (628.7 mg) as an orange oil and used without further 
purification. 1H NMR (500 MHz, CDCl3) d 7.38 (d, 2H, J = 8.6 Hz), 7.03 (d, 2H, J = 8.6 Hz), 
5.29 (s, 2H), 2.82 (s, 4H). 
 
3-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)phenyl(4-azidobenzyl)carbonate 
(7a). Compound 5a (77 mg, 0.29 mmol, 1.0 equiv) was dissolved in 1.5 mL 4:1 THF:CH2Cl2 in a 
dry flask under N2 atmosphere. Compound 6 (126 mg, 0.44 mmol, 1.5 equiv) was added as a 
solution in 1.5 mL CH2Cl2. DMAP (53 mg, 0.44 mmol, 1.5 equiv) and NEt3 (124 µL, 0.899 
mmol, 3.1 equiv) were then added in succession. After 14 h of stirring at rt, the mixture was 
poured into a separatory funnel containing 20 mL CH2Cl2 and 15 mL DI-H2O and extracted with 
3 x 20 mL CH2Cl2. The organic layer was washed with 10 mL brine, dried over Na2SO4, filtered, 
and concentrated. Purification by silica column chromatography (1:15 EtOAc/hexanes) afforded 
7a as a clear oil (84 mg, 62%). 1H NMR (500 MHz, CDCl3) d 7.43 (d, 2H, J = 8.6 Hz), 7.34 (t, 
1H, J = 7.5 Hz), 7.18–7.20 (m, 1H), 7.06–7.12 (m, 2H), 7.04 (d, 2H, J = 8.6 Hz), 5.23 (s, 2H), 
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3.29 (s, 3H), 3.24 (s, 1H), 2.64 (s, 1H), 1.65–2.10 (m, 12H); 13C NMR (125 MHz, CDCl3) d 
153.51, 150.84, 142.52, 140.61, 137.13, 132.78, 131.36, 130.30, 128.94, 126.97, 121.68, 119.82, 
119.23, 69.66, 57.90, 39.11, 38.99, 37.07, 32.09, 30.22, 28.19; HRMS calcd for C26H27N3O4 
(M+H+) 446.2074, found 446.2073. 
 
5-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)-2-fluorophenyl(4-
azidobenzyl)carbonate (7b). Compound 5b (123 mg, 0.427 mmol, 1.0 equiv) was dissolved in 
3.5 mL 4:1 THF:CH2Cl2 in a dry flask under N2 atmosphere. Compound 6 (186 mg, 0.641 mmol, 
1.5 equiv) was added as a solution in 3.3 mL CH2Cl2, followed directly by the addition of DMAP 
(78.3 mg, 0.641 mmol, 1.5 equiv) and NEt3 (185 µL, 1.32 mmol, 3.1 equiv). After 14 h of 
stirring at rt, the mixture was poured into a separatory funnel containing 30 mL CH2Cl2 and 20 
mL DI-H2O and extracted with 3 x 30 mL CH2Cl2. The organic layer was washed with 10 mL 
brine, dried over Na2SO4, filtered, and concentrated. Purification by silica column 
chromatography (1:15 EtOAc/hexanes) afforded 7b as a clear oil (125 mg, 63%). 1H NMR (500 
MHz, CDCl3) d 7.43 (d, 2H, J = 8.0 Hz), 7.10–7.20 (m, 3H), 7.05 (d, 2H, J = 8.0 Hz), 5.25 (s, 
2H), 3.28 (s, 3H), 3.22 (s, 1H), 2.60 (s, 1H), 1.53–2.10 (m, 12H); 13C NMR (125 MHz, CDCl3) d 
153.98, 152.66, 141.64, 140.69, 132.98, 132.29, 131.12, 130.25, 128.16, 123.89, 119.25, 116.38, 
116.24, 70.18, 57.90, 39.08, 38.96, 37.02, 32.11, 30.24, 28.14; LRMS (MALDI) calcd for 
C26H26ClN3O4 (M+) 463.1907, found 463.3052. 
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5-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)-2-chlorophenyl(4-
azidobenzyl)carbonate (7c). Compound 5c (66.6 mg, 0.218 mmol, 1.0 equiv) was dissolved in 
1.5 mL 4:1 THF: CH2Cl2 in a dry flask under N2 atmosphere. Compound 6 (76.6 mg, 0.262 
mmol, 1.2 equiv) was added as a solution in 1.2 mL CH2Cl2. DMAP (40.0 mg, 0.327 mmol, 1.5 
equiv) and NEt3 (95 µL, 0.68 mmol, 3.1 equiv) were then added in succession. After 14 h of 
stirring at rt, the mixture was poured into a separatory funnel containing 20 mL CH2Cl2 and 10 
mL DI-H2O and extracted with 3 x 20 mL CH2Cl2. The organic layer was washed with 10 mL 
brine, dried over Na2SO4, filtered, and concentrated. Purification by silica column 
chromatography (1:15 EtOAc/hexanes) afforded 7c as a clear oil (53 mg, 51%). 1H NMR (500 
MHz, CDCl3) d 7.43 (d, 2H, J = 8.6 Hz), 7.39 (d, 1H, J = 8.1 Hz), 7.15–7.17 (m, 2H), 7.05 (d, 
2H, J = 8.6 Hz), 5.26 (s, 2H), 3.30 (s, 3H), 3.22 (s, 1H), 2.63 (s, 1H), 1.56–2.00 (m, 12H); 13C 
NMR (125 MHz, CDCl3) d 152.53, 146.75, 141.60, 140.66, 135.76, 133.75, 131.22, 130.24, 
129.86, 128.13, 125.37, 123.76, 119.23, 70.12, 58.04, 39.09, 38.07, 37.00, 32.15, 30.31, 28.14; 
LRMS (MALDI) calcd for C26H26ClN3O4 (M+) 479.1612, found 479.2970. 
 
4-azidobenzyl(3-((1r,3r,5r,7r)-4'-methoxyspiro[adamantane-2,3'-[1,2]dioxetan]-4'yl) 
phenyl)carbonate(CHS-1). Compound 7a (75 mg, 0.17 mmol, 1.0 equiv) and Rose bengal (8.5 
mg, 0.0087 mmol, 0.051 equiv) were added into a dry flask and dissolved in 5 mL THF. Oxygen 
was bubbled through the reaction mixture, while irradiating with a 120 W light bulb (Home 
Depot, Dallas, TX) at 0 °C. After 3.5 h of reaction, TLC showed no starting material left and the 
mixture was then concentrated under vacuum at 0 ºC and the residue was purified by the silica 
column chromatography (1:15 EtOAc/hexanes) to deliver CHS-1 as a white solid (56.4 mg, 
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70 %). 1H NMR (500 MHz, CDCl3) d 7.42–7.92 (br m, 3H), 7.42–7.44 (m, 2H), 7.23 (dd, 1H, J 
= 9.2, 2.3 Hz), 7.05 (d, 2H, J = 8.6 Hz), 5.23 (s, 2H), 3.21 (s, 3H), 3.02 (s, 1H), 2.12 (s, 1H), 
1.20–1.90 (m, 12H); 13C NMR (125 MHz, CDCl3) d 153.43, 151.08, 140.82, 136.73, 131.34, 
130.42, 129.33, 122.10, 119.39, 111.58, 95.52, 69.94, 50.13, 36.44, 34.74, 32.94, 32.82, 32.35, 
31.77, 31.50 25.93, 25.81. 
 
4-azidobenzyl(2-fluoro-5-((1r,3r,5r,7r)-4'-methoxyspiro[adamantane-2,3'-[1,2]dioxetan]-4'-
yl)phenyl)carbonate (CHS-2). Compound 7b (47.6 mg, 0.103 mmol, 1 equiv) and Rose bengal 
(7 mg, 0.007 mmol, 0.07 equiv) were added into a dry flask and dissolved in 5.0 mL THF. 
Oxygen was bubbled through the reaction mixture, while irradiating with a 120 W light bulb 
(Home Depot, Dallas, TX) at 0–5 °C. After 6 h of reaction, the mixture was concentrated under 
vacuum at 0 ºC. Purification by silica column chromatography (1:15 EtOAc/hexanes) provided 
CHS-2 as a white solid (32.5 mg, 66%). 1H NMR (500 MHz, CDCl3) d 7.40–7.91 (br m, 2H), 
7.41–7.44 (m, 2H), 7.20–7.24 (m, 1H), 7.04–7.06 (d, 2H, J = 8.6 Hz), 5.25 (s, 2H), 3.21 (s, 3H), 
3.01 (s, 1H), 2.07 (s, 1H), 0.90–2.00 (m, 12H); 13C NMR (125 MHz, CDCl3) d 155.47, 153.46, 
152.48, 140.79, 138.33, 131.61, 130.98, 130.26, 119.29, 116.82, 116.67, 111.06, 95.37, 70.34, 
50.00, 39.25, 36.26, 34.78, 33.13, 32.87, 32.19, 31.67, 31.50, 25.93, 25.78. 
 
4-azidobenzyl(2-chloro-5-((1r,3r,5r,7r)-4'-methoxyspiro[adamantane-2,3'-[1,2]dioxetan]-4'-
yl)phenyl)carbonate (CHS-3).  Compound 7c (37.3 mg, 0.0777 mmol, 1 equiv) and Rose 
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bengal (6 mg, 0.006 mmol, 0.08 equiv) were added into a dry flask and dissolved in 4.0 mL THF. 
Oxygen was bubbled through the reaction mixture, while irradiating with a 120 W light bulb 
(Home Depot, Dallas, TX) at 0–5 °C. The reaction was monitored by TLC. When TLC showed 
no starting material, the mixture was concentrated under vacuum at 0 ºC. The residue was 
purified by silica column chromatography (1:15 EtOAc/hexanes). Compound CHS-3 was 
obtained as white solid (36.1 mg, 91%). 1H NMR (500 MHz, CDCl3) d 7.10–7.89 (br m, 2H), 
7.49–7.56 (m, 1H), 7.42–7.44 (m, 2H), 7.03–7.07 (m, 2H), 5.26 (s, 2H), 3.21 (s, 1H), 3.01 (s, 
1H), 2.07 (s, 1H), 0.96–1.90 (m, 12H); 13C NMR (125 MHz, CDCl3) d 152.41, 147.07, 140.76, 
135.31, 131.07, 130.23, 130.10, 128.12, 119.26, 111.00, 95.38, 70.28, 50.04, 36.25, 34.78, 33.11, 
32.93, 32.17, 31.69, 31.50, 25.93, 25.78; LRMS (ESI) calcd for C26H26ClN3O6Na (M+Na+) 
534.1408, found 534.200. 
 
2.4.2 Chemiluminescent response 
Chemiluminescent responses and time scans were acquired using a Hitachi F-7000 
Fluorescence Spectrophotometer (Hitachi, Tokyo, Japan) using the luminescence detection 
module and setting emission wavelength at 545 nm. 393 µL of a 20 mM HEPES buffered to pH 
7.4 (Figure 1-1) or 100 mM glycine buffered to pH 10.02, 100 µL Emerald II Enhancer (Life 
Technologies, Carlsbad, CA), 5 µL of a 20 mM Na2S stock solution in DI-H2O and 2 µL of a 10 
mM stock solution of CHS probes in CH3CN were added to a quartz cuvette (Starna, Atascadero, 
CA). Samples were shaken gently to assure mixing. Then chemiluminescent spectra were 
acquired immediately after adding the probes. Time scans were acquired using the time scan 
module. 40 µM CHS-1, CHS-2, and CHS-3 were treated with 0, 5, 10, 20, 40, 80, 100, 150, and 
200 µM Na2S, and 10 min or 120 min time scans were measured 1 min after adding probes.  
  55 
2.4.3 Selectivity tests 
Selectivity for CHS-1, CHS-2, and CHS-3 was measured by monitoring the time-
dependent chemiluminescence emission at 545 nm. All assays were performed in 20 mM HEPES 
buffered to pH 7.4 with 20% Emerald II Enhancer. 
H2S: 5 µL of a 20 mM stock solution of Na2S in DI-H2O was added to a solution of 393 µL 
HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 in 
CH3CN was added into this mixture. 
H2S, GSH, cysteine and Hcy: 5 µL of a 20 mM stock solution of Na2S in DI-H2O, 25 µL of a 100 
mM stock solution of GSH in 20 mM HEPES buffer, 5 µL of a 100 mM stock solution of L-
cysteine in DI-H2O and 5 µL of a 100 mM stock solution of Hcy in DI-H2O were added to a 
solution of 358 µL HEPES and 100 µL Emerald II Enhancer, mixed them well and then 2 µL of 
10 mM CHS-1, CHS-2, or CHS-3 in CH3CN was added into this mixture. 
GSH: 25 µL of a 100 mM stock solution of GSH in 20 mM HEPES buffer was added to a 
solution of 373 µL HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, 
CHS-2, or CHS-3 in CH3CN was added into this mixture. 
S-nitrosoglutathione: 2 µL of a 50 mM stock solution of S-nitrosoglutathione in DI-H2O was 
added to a solution of 396 µL HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM 
CHS-1, CHS-2, or CHS-3 in CH3CN was added into this mixture. 
Cysteine: 5 µL of a 100 mM stock solution of L-cysteine in DI-H2O was added to a solution of 
393 µL HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or 
CHS-3 in CH3CN was added into this mixture. 
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Hcy: 5 µL of a 100 mM stock solution of Hcy in DI-H2O was added to a solution of 393 µL 
HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 in 
CH3CN was added into this mixture. 
HNO: Angeli’s salt (Na2N2O3) was used to generate HNO. The stock solution was made by 
dissolving Angeli’s salt in 0.01 M NaOH solution immediately prior to use. The concentration of 
this alkaline stock solution of Angeli's salt was measured by UV/Vis using e = 6100 M–1 cm–1 at 
237 nm. 4 µL of a 25 mM stock solution of Angeli’s salt was added to a solution of 394 µL 
HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 in 
CH3CN was added into this mixture. 
NO: PROLI NONOate was used to generate NO. It was stored at –80 °C and dissolved in 0.01 M 
NaOH solution immediately prior to use. The concentration of this alkaline stock solution of 
PROLI NONOate was measured by UV/Vis using e = 8400 M–1 cm–1 at 252 nm. 8 µL of a 12.5 
mM stock solution of PROLI NONOate was added to a solution of 390 µL HEPES and 100 µL 
Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 in CH3CN was added 
into this mixture.  
NaNO2: 1 µL of a 100 mM stock solution of NaNO2 in DI-H2O was added to a solution of 397 
µL HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 
in CH3CN was added into this mixture. 
Na2SO3: 1 µL of a 100 mM stock solution of Na2SO3 in DI-H2O was added to a solution of 397 
µL HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 
in CH3CN was added into this mixture.  
  57 
H2O2: 0.5 µL of a 200 mM stock solution of H2O2 in DI-H2O was added to a solution of 397.5 µL 
HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 in 
CH3CN was added into this mixture. 
OCl–: 1 µL of a 100 mM stock solution of OCl– in DI-H2O was added to a solution of 397 µL 
HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 in 
CH3CN was added into this mixture. 
tBuOOH: 1 µL of a 100 mM stock solution of tBuOOH in DI-H2O was added to a solution of 397 
µL HEPES and 100 µL Emerald II Enhancer and then 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 
in CH3CN was added into this mixture.  
Blank: 2 µL of 10 mM CHS-1, CHS-2, or CHS-3 in CH3CN was added to a solution of 398 µL 
HEPES and 100 µL Emerald II Enhancer. 
 
2.4.4 Computational results 
All the geometries were optimized using density functional theory (DFT) with 
B3LYP46,47,48,49 functional and Pople basis set 6-311+G(d,p)50 and integral equation formalism of 
polarizable continuum model (IEF-PCM)51 with water as solvent. Atomic charges are calculated 
using ESP model.52 The ESP charges were also calculated at using M0653 and ωB97XD54 
functionals and 6-311+G(d,p) basis set using IEF-PCM with water as solvent at geometries 
optimized at B3LYP/6-311+G(d,p) level of theory. All the calculations were carried out using 
Gaussian09.55  
 
Table 2-1. Cartesian coordinates and ESP charges of the phenolate released from CHS-1. 
 





Coordinates ESP Charges 
X Y Z         B3LYP     M06 ωB97XD 
C  -0.525984   1.150508   -0.203135  0.545303  0.471105  0.495804 
C  -1.727570   0.285391    0.124617  0.099203  0.109287  0.117666 
C  -2.083655   0.092001    1.470495 -0.271377 -0.284134 -0.297094 
C  -3.175031  -0.730180    1.760514 -0.119742 -0.103717 -0.119251 
C  -3.910823  -1.346960    0.754537 -0.489714 -0.496664 -0.505737 
C  -3.590809  -1.171395   -0.630272  0.732688  0.718372  0.726573 
C  -2.458164  -0.327224   -0.890878 -0.482501 -0.479113 -0.497363 
H  -2.177752  -0.170785   -1.926113  0.134117  0.133390  0.146024 
H  -1.524221   0.571638    2.263229  0.127048  0.128149  0.141148 
H  -3.457109  -0.889776    2.798020  0.132324  0.132286  0.144371 
H  -4.757334  -1.980048    1.006384  0.158441  0.159698  0.170194 
O   0.886032   1.289159   -1.758716 -0.234040 -0.220551 -0.218705 
O  -0.552137   1.592492   -1.592039 -0.274019 -0.253500 -0.257995 
O  -0.388964   2.245425    0.662459 -0.359828 -0.340657 -0.344376 
C  -1.458996   3.199452    0.641049 -0.051678 -0.065903 -0.097505 
H  -1.581264   3.620117   -0.360353  0.065677  0.073081  0.082881 
H  -2.400056   2.752689    0.970625  0.046074  0.053406  0.062674 
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C   0.894931   0.542654   -0.476542 -0.301032 -0.315180 -0.331668 
C   2.072956   0.986778    0.395329  0.459439  0.424814  0.466294 
C   0.982428  -0.967402   -0.749027  0.477663  0.443191  0.485612 
C   3.387488   0.686966   -0.361529 -0.516053 -0.509129 -0.576764 
H   1.987177   2.056259    0.588102 -0.008413  0.006917  0.008296 
C   2.058656   0.202573    1.726486 -0.545194 -0.536331 -0.607069 
C   0.980257  -1.748010    0.585087 -0.622453 -0.594505 -0.674162 
C   2.300998  -1.258371   -1.500814 -0.561967 -0.543775 -0.618448 
H   0.129315  -1.269331   -1.360870  0.021265  0.029948  0.033563 
H   4.232097   1.032165    0.244944  0.105916  0.112922  0.129743 
H   3.419685   1.247622   -1.301616  0.105207  0.113368  0.128594 
C   3.502403  -0.823911   -0.638910  0.667617  0.611593  0.670457 
H   2.895262   0.542800    2.347007  0.123243  0.128594  0.147093 
H   1.140768   0.414965    2.283265  0.088636  0.098837  0.113524 
C   2.177369  -1.308027    1.448003  0.642633  0.596155  0.651186 
H   0.044439  -1.583005    1.124784  0.124333  0.119936  0.144045 
H   1.041301  -2.819977    0.366152  0.130318  0.133016  0.152250 
H   2.313705  -0.730443   -2.459250  0.111743  0.117263  0.133609 
H   2.355114  -2.329825   -1.722358  0.115670  0.119557  0.138788 
C   3.491446  -1.595465    0.695969 -0.615873 -0.609456 -0.682179 
H   3.588945  -2.671348    0.509269  0.115291  0.122012  0.139607 
H   4.349881  -1.296970    1.309330  0.107426  0.115414  0.132729 
H   4.433667  -1.028357   -1.177878 -0.075734 -0.056419 -0.058091 
O8  -4.262270  -1.729367   -1.578754 -0.945304 -0.924794 -0.945863 
H   2.166090  -1.856290    2.395996 -0.058611 -0.041926 -0.042532 
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Coordinates ESP Charges 
X Y Z 
        
B3LYP 
    M06 ωB97XD 
 C   0.149490   1.295067  0.147303  0.666428  0.613317  0.635134 
 C   1.447231   0.538942 -0.058484  0.027595  0.039860  0.041685 
 C   1.888437   0.280587 -1.364665 -0.227740 -0.236361 -0.248862 
 C   3.069166  -0.445270 -1.543795 -0.313850 -0.299083 -0.314726 
 C   3.778432  -0.886334 -0.446454  0.164508  0.153261  0.151692 
 C   3.403682  -0.658579  0.912787  0.533141  0.527766  0.531079 
 C   2.183736   0.082379  1.035332 -0.460427 -0.466600 -0.478759 
 H   1.837314   0.289506  2.040882  0.156613  0.157543  0.168896 
 H   1.330477   0.635373 -2.220796  0.146178  0.145784  0.158982 
 H   3.442171  -0.668581 -2.538004  0.189167  0.189068  0.201163 
 O  -1.329697   1.410147  1.641708 -0.221708 -0.205948 -0.205321 
 O   0.071893   1.857398  1.489683 -0.299493 -0.282719 -0.286349 
 O  -0.061869   2.285941 -0.821477 -0.377468 -0.362749 -0.365580 
 C   0.891813   3.356861 -0.842148 -0.081532 -0.095256 -0.128613 
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 H   1.895042   2.995397 -1.080186  0.048046  0.053884  0.064272 
 H   0.555873   4.040912 -1.620331  0.107245  0.114679  0.123568 
 C  -1.210061   0.563606  0.429631 -0.410019 -0.439958 -0.450678 
 C  -2.391332   0.806026 -0.514636  0.550796  0.513778  0.556319 
 C  -1.151011  -0.920189  0.826641  0.543890  0.511907  0.555224 
 C  -3.697592   0.428257  0.220997 -0.589371 -0.579830 -0.649153 
 H  -2.410032   1.859872 -0.793122 -0.015794  0.000026  0.001376 
 C  -2.239512  -0.075751 -1.773927 -0.601316 -0.585706 -0.660233 
 C  -1.011108  -1.799538 -0.436741 -0.698894 -0.666739 -0.749373 
 C  -2.461963  -1.290788  1.555754 -0.639683 -0.616966 -0.693655 
 H  -0.298253  -1.080127  1.490472  0.020949  0.028655  0.031905 
 H  -4.547150   0.629361 -0.440989  0.121087  0.127371  0.144632 
 H  -3.828272   1.057647  1.107516  0.122295  0.130426  0.145595 
 C  -3.665526  -1.058674  0.621959  0.723048  0.664696  0.725968 
 H  -3.080441   0.121741 -2.448015  0.130847  0.135013  0.154067 
 H  -1.326501   0.187841 -2.316539  0.093118  0.101384  0.117278 
 C  -2.211125  -1.562837 -1.372594  0.720043  0.668780  0.726384 
 H  -0.076344  -1.578680 -0.958022  0.130602  0.125136  0.149630 
 H  -0.968073  -2.850972 -0.131205  0.148104  0.149685  0.169644 
 H  -2.569150  -0.693651  2.466582  0.132276  0.137128  0.153565 
 H  -2.412389  -2.340833  1.863828  0.133851  0.136174  0.155828 
 C  -3.517799  -1.929125 -0.642510 -0.729769 -0.717799 -0.794224 
 H  -3.508855  -2.990497 -0.368443  0.144229  0.149606  0.167941 
 H  -4.376625  -1.775332 -1.306291  0.133322  0.140041  0.158105 
 H  -4.591809  -1.318302  1.145321 -0.069040 -0.050168 -0.051929 
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 O8   4.088841  -1.078040  1.913968 -0.880513 -0.862369 -0.882378 
 H  -2.102631  -2.181758 -2.269492 -0.057694 -0.041053 -0.041458 
 F   4.938444  -1.596528 -0.673229 -0.286675 -0.285937 -0.279140 
 
 






Coordinates ESP Charges 
X Y Z 
        
B3LYP 
    M06 ωB97XD 
C    -0.226616   1.379308    0.084256  0.477044  0.391441  0.434096 
C     1.136262   0.725086   -0.038113  0.275155  0.290053  0.286684 
C     1.629921   0.398308   -1.312558 -0.304850 -0.316975 -0.331510 
C     2.869203  -0.231300   -1.410975 -0.140200 -0.104783 -0.128008 
C     3.603953  -0.523739   -0.270801 -0.197996 -0.250474 -0.222810 
C     3.169669  -0.211460    1.060595  0.789065  0.792540  0.789128 
C     1.883594   0.429928    1.096313 -0.669246 -0.662266 -0.678151 
H     1.500428   0.687659    2.076325  0.185804  0.183499  0.196519 
H     1.064628   0.630276   -2.205377  0.146778  0.146802  0.160845 
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O    -1.739421   1.449315    1.548388 -0.250273 -0.236758 -0.234096 
O    -0.386703   2.022435    1.381224 -0.269303 -0.248082 -0.254511 
O    -0.491411   2.279085   -0.956871 -0.375806 -0.353336 -0.360094 
C     0.373729   3.420331   -1.035139 -0.037390 -0.053041 -0.084873 
H     0.315745   4.011511   -0.117817  0.068619  0.076932  0.086152 
H     1.409742   3.125859   -1.219015  0.031909  0.038941  0.048745 
H     0.009101   4.014271   -1.872134  0.098118  0.105477  0.114263 
C    -1.524543   0.550098    0.387797 -0.220732 -0.229779 -0.256661 
C    -2.704067   0.643036   -0.584689  0.460276  0.424371  0.468665 
C    -1.352091  -0.899530    0.867956  0.502259  0.465498  0.514064 
C    -3.987842   0.203875    0.156948 -0.558241 -0.548514 -0.619949 
H    -2.801982   1.674432   -0.923733  0.001334  0.015586  0.017705 
C    -2.462727  -0.293736   -1.789133 -0.562438 -0.547368 -0.624448 
C    -1.122839  -1.834929   -0.341825 -0.666226 -0.632362 -0.717206 
C    -2.641055  -1.333302    1.602224 -0.639705 -0.614850 -0.696101 
H    -0.500127  -0.952239    1.549769  0.017717  0.025071  0.028669 
H    -4.840580   0.299402   -0.524073  0.119066  0.125338  0.142934 
H    -4.180994   0.868846    1.005179  0.116431  0.123826  0.139779 
C    -3.844179  -1.250708    0.642918  0.680415  0.619023  0.684559 
H    -3.305652  -0.202710   -2.483282  0.131749  0.135932  0.155508 
H    -1.565258   0.011735   -2.335771  0.087984  0.096743  0.112776 
C    -2.322938  -1.748524   -1.302431  0.638117  0.583720  0.647335 
H    -0.200433  -1.569401   -0.864446  0.125111  0.119818  0.144461 
H    -1.000393  -2.860142    0.024952  0.146882  0.148543  0.168391 
H    -2.810960  -0.696788    2.475937  0.132890  0.136716  0.154634 
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H    -2.513222  -2.357182    1.969865  0.138955  0.141353  0.161574 
C    -3.607974  -2.176718   -0.567081 -0.680569 -0.667777 -0.747001 
H    -3.519229  -3.217008   -0.232864  0.139088  0.144225  0.163023 
H    -4.465128  -2.130460   -1.249182  0.127329  0.134405  0.152458 
H    -4.755108  -1.553702    1.169924 -0.060987 -0.041332 -0.043684 
O     3.839950  -0.470633    2.117156 -0.907189 -0.894123 -0.909589 
H    -2.151668  -2.406450   -2.160957 -0.041069 -0.023678 -0.025356 




Figure 2-11. Plot of the integrated chemiluminescence emission over 10 min at pH 10 of 200 
µM H2S and 40 µM CHS-1 (red), CHS-2 (green) and CHS-3 (blue) versus the calculated 
atomic charges on the phenolate oxygen (O8). All luminescent measurements were acquired in 
100 mM glycine (pH 10) containing 20% Emerald II Enhancer. The reported values are 
averages of the integrated emission intensities over 10 min (n = 4–7). Error bars represent ± 
S.D. Geometries were optimized with B3LYP/6-311G+(d,p) and ESP atomic charges were 
calculated with (a) B3LYP/6-311+G(d,p) or (b) ωB97XD/6-311+G(d,p). Calculations were 
carried out with the IEF-PCM water solvation model using Gaussian 09. (Data was collected 
by Tao group) 
 
2.4.5 Cellular experiments 
Chemiluminescent response using a multi-well plate reader. Chemiluminescent responses were 
measured using a BioTek plate reader (Winooski, VT) by using the luminescence detection 
method, endpoint read type, and setting sensitivity to 135. 120 µL, 119 µL, 119 µL, 118 µL, and 
(a) (b) 
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116 µL of 20 mM HEPES buffer (pH 7.4) were added into the wells of a black opaque Corning® 
96-well plate from A1 to A5 in sequence, 30 µL Emerald II Enhancer was pipetted into each 
well, then different volumes of a 10 mM Na2S solution (0 µL, 0.38 µL, 0.75 µL, 1.5 µL, 3.0 µL) 
were added into each well. 0.60 µL CHS-3 was injected into each well and the luminescent 
intensity of the plate was measured every 2 min after addition of probes. The detection limit was 
estimated as the amount of Na2S required to give a chemiluminescent signal above three times 
the standard deviation of at least 3 independent experiments with 0 µM Na2S. The concentration 
of Na2S needed was estimated by fitting a line to the linear region of the curve between the data 
points corresponding to 0 µM Na2S and 25 µM Na2S. 
 
Cell culture and detecting cellular H2S using a multi-well plate reader. Human lung 
adenocarcinoma epithelial cell (A549) were purchased from ATCC and cultured in F-12K media 
supplemented with 10% Fetal Calf Serum (FCS) at 37 °C with 5% CO2. Two days before the 
experiment, cells were passed and plated on Costar® 12-well plates by adding 150K–175K of 
A549 cells per well, filling each well up to 600 µL of media with FCS, and aspirating the media 
upon 90–95% confluence. Cells were serum-starved for 18 h prior to the experiment. Stock 
solutions of 20 mM Hcy and 20 mM DL-propargyl glycine (PAG) were prepared in 20 mM 
HEPES buffer (pH 7.4) and 10 mM CHS-3 was prepared in CH3CN. 6 µL PAG (final 
concentration: 200 µM) was added to C1–C3 of the 12-well plate. After 20 min incubation, 6 µL 
Hcy (final concentration: 200 µM) was added into B1–B3 and C1–C3 of the 12-well plate, and 6 
µL 20 mM HEPES buffer (pH 7.4) as a vehicle control was added to A1–A3. After another 20 
min incubation, cells were washed with 1 x PBS. Then 500 µL PBS media was added into each 
well after aspirating the media. 125 µL Emerald II Enhancer and 2.7 µL CHS-3 (final 
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concentration: 40 µM) were added to each well and the luminescent intensity was measured 
every two minutes for 20 minutes. The experiment was repeated with four independent well 
plates and the peak value for the luminescence emission for each well at 10–12 minutes was 
normalized to the average luminescence emission at 10–12 minutes for the control replicates of 
each plate. A single outlier was rejected according to the extreme studentized deviate method 
(Grubbs' test, p < 0.01). 
 
2.4.6 Imaging experiments 
Chemiluminescence imaging at pH 7.4. Imaging was carried out with a Caliper Xenogen IVISÒ 
Spectrum (Perkin-Elmer, Santa Clara, CA) in black 96-well CostarÒ plates and all the images 
were analyzed using Living Image 3.1 software. 10 mM CHS-3 in CH3CN and 10 mM Na2S in 
DI-H2O were prepared prior to imaging. 199 µL, 198 µL, 198 µL, 197 µL and 195 µL of 20 mM 
HEPES buffer (pH 7.4) were added into wells from A1 to A5 in sequence, 50 µL Emerald II 
Enhancer was pipetted into each well, then different volume of Na2S solution (0 µL, 0.61 µL, 
1.25 µL, 2.5 µL, 5.0 µL) were added into each well. 1 µL CHS-3 was injected into the mixture 
and imaging was performed after 30 seconds using an open filter. All images were acquired with 
f-stop 1, medium binning, auto exposure and the chamber set to 37 °C. 
 
Imaging H2S in mouse carcass. A stock solution of 25 mM CHS-3 in DMSO and 50 mM Na2S in 
DI-H2O were prepared in advance. The 50 mM stock solution of Na2S was diluted to provide a 
final concentration of 4 mM Na2S in 100 µL (0.4 µmol) to be injected. Images were acquired 30 
second after administering i.p. injections to the carcasses of SCID/BALB-C mice with 0.08 µmol 
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CHS-3 and either 0.4 µmol Na2S or a vehicle control (H2O) in HEPES buffered at pH 7.4 
containing 20% Emerald II Enhancer. 
 
Imaging H2S in living mice. The UT Southwestern Institutional Animal Care and Use Committee 
approved these investigations under APN #2009-0150. A stock solution of 25 mM CHS-3 in 
DMSO and 50 mM Na2S in DI-H2O were prepared in advance. 68.8 µL of 20 mM HEPES 
buffer (pH 7.4), 20 µL Emerald II Enhancer, 8 µL Na2S solution and 3.2 µL CHS-3 were 
intraperitoneally injected into C6 brown mice, lifting the skin to avoid puncture of internal 
organs. Imaging was performed 30 second after injecting using an open filter to maximize light 
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CHAPTER 3 




Hypoxia is a pathogenic condition of low tissue oxygenation. It is a characteristic of solid 
tumors.1 Cancer cells undergo a variety of biological changes to support their survival in hypoxia 
or low tissue oxygenation conditions, including proliferation and angiogenesis.2 The most 
significant and important biological response to low oxygen conditions is the activation of the 
transcription factor hypoxia inducible factor 1α (HIF-α). In normoxia, HIF-α is hydroxylated in 
the presence of oxygen (O2), iron (Fe2+), and prolyl hydroxylase enzymes, increasing its chance 
of binding to Von Hippel-Lindau, a tumor suppressor protein, which targets its ubiquitination 
and mediates its degradation.2e,3 In hypoxia, HIF-α dimerizes with HIF-β, and transcriptionally 
regulates hypoxia-responsive genes to support cancer cell survival.2e,4 Some reductive 
mammalian enzymes, such as xanthine oxidase, NADPH-cytochrome c reductases, and 
potentially cytosol DT diaphorase, aldehyde oxidase, and lipoyl dehydrogenase5 have been 
widely used as biomarkers for hypoxia using selective bioreduction of  nitroaromatic compounds 
under hypoxic conditions (Scheme 3-1).6 Imaging agents like FMISO7 and 
immunohistochemical stains like pimonidazole8 targets these reductive enzymes. GSH, 
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thioredoxin, reduced nicotinamide adenine dinucleotide (NADH), and vitamin C are several 
other important redox systems playing fundamental roles in biological systems.9 
 
 
Scheme 3-1. Proposed mechanism of bioreduction in hypoxic conditions. 
 
Classic methods for low tissue oxygenation and hypoxia measurement include oxygen 
electrodes,10 PET,11 MRI,12 and multispectral optoacoustic tomography (MSOT).13 Even though 
they offer accurate detection and diagnosis of hypoxia and tissue oxygenation, they are either 
invasive or require expensive instrumentation and highly trained experts. Over the last three 
decades, optical imaging techniques have received tremendous attention, and reaction-based 
probes have been widely used for interrogating biological species. Reductive enzymes are well 
accepted biomarkers for targeting poorly oxygenated and hypoxic tissue.5 Reductases, a class of 
flavin-containing enzymes for the oxygen-dependent reduction of nitroaromatics to amines, have 
become a well-established method for sensing tissue oxygenation and hypoxia.14 Recently, 
several reaction-based fluorescent15 and bioluminescent probes16 for nitroreductase and hypoxia 
have been reported. For fluorescent detection, the dyes must be first excited by an external light 
source, which generates a significant amount of autofluorescence and light scattering. A 
genetically modified biological system is required for bioluminescence imaging.31 To offer better 
imaging agents for hypoxia, our group initiated a project for detecting nitroreductase and 
hypoxia using reaction-based chemiluminescent probes.  
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Scheme 3-2. Spiroadamantane 1,2-dioxetanes for chemiluminescent nitroreductase detection at 
neutral pH. 
 
A spiroadamantane 1,2-dioxetane scaffold was selected to make reaction-based 
chemiluminescent probes because this structure has already been demonstrated to be capable of 
in vivo imaging of galactosidase38 and H2S.17 Our design strategy for reaction-based 
chemiluminescent probes for hypoxia relies on tethering a para-nitrobenzyl moiety to a 
spiroadamantane 1,2-dioxetane chemiluminescent scaffold via carbonate or ether linkage 
(Scheme 3-2). The Hypoxia Chemiluminescent Probe 1 (HyCL-1) was synthesized by the 
dimethylaminopyridine-catalyzed coupling of the previously reported phenol 5c17 with 
compound 8 to provide the precursor 9. This precursor 9 was subjected to [2+2] cycloaddition by 
bubbling oxygen through the reaction mixture using Rose bengal as a sensitizer with light 
irradiation to afford HyCL-1. For Hypoxia Chemiluminescent Probe 2 (HyCL-2), the precursor 
11 was obtained by Mitsunobu reaction18 between phenol 5c and para-nitrobenzyl alcohol 10 
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Scheme 3-3. Synthesis of HyCL-1 and HyCL-2. 
 
3.2 Results and discussion 
After obtaining HyCL-1 and HyCL-2, we started to collect their absorption (Figure 3-1) 
and emission (Figure 3-2) spectra and measure their luminescent responses to nitroreductase 
from Escherichia coli in the presence of NADH. Luminescent response toward nitroreductase 
was evaluated in PBS (10 mM, pH 7.4) buffer containing 10% Emerald II Enhancer. Treatment 
of 10 µM of HyCL-1 and HyCL-2 with 14 µg/ml nitroreductase, 0.4 mM NADH, and 10% 
Emerald II Enhancer resulted in instantaneous luminescence emissions centered at 545 nm that 
increased over a time course of 60 minutes (Figure 3-5), providing a ~5-fold and ~170-fold 
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response is dose-dependent with good linearity in the range of 0–14 µg/mL of nitroreductase 
(Figure 3-4). Furthermore, the ether-linked HyCL-2 showed a much lower background emission 
(Figure 3-3b, red scan) compared with the carbonate linked HyCL-1 (Figure 3-3a, red scan). To 
better understand nitro reduction by reductase enzymes, a GC-MS experiment was conducted by 
analyzing the reaction products between HyCL-2, NADH, and nitroreductase, indicating the 
generation of 2-adamantanone (Figure 3-14) and methyl 4-chloro-3-hydroxybenzoate (Figure 3-
15), whose fragmentation patterns match the spectra found in the NIST database. A molecular 
ion at m/z = 121 was also observed that was assigned to 4-methylenecyclohexa-2,5-dien-1-one 
oxime (Figure 3-16), consistent with previous reports that the nitro group was reduced to a 
hydroxylamine,19 followed by a self-immolative cleavage to generate the dioxetane phenolate. 
 
 
Figure 3-1. Chemiluminescence emission spectra of (a) 10 µM HyCL-1 and (b) 10 µM HyCL-2 
with 0 (grey) and 14 (black) µg/mL nitroreductase in the presence of 0.4 mM NADH in 10 mM 
PBS buffer (pH 7.4) containing 10% Emerald II Enhancer acquired 30 min after adding 
nitroreductase. 
(a) (b)
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Figure 3-2. Chemiluminescent absorption spectra of (a) 10 µM HyCL-1 and (b) 10 µM HyCL-2 




Figure 3-3. Time scans of the chemiluminescence emission at 545 nm from (a) 10 µM HyCL-1 
and (b) 10 µM HyCL-2 and 0, 2.5, 5, 7.5, 10, 12.5, 14 µg/mL nitroreductase in the presence of 
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Figure 3-4. Chemiluminescence emission at 545 nm from (a) 10 µM HyCL-1 and (b) 10 µM 
HyCL-2 and 0, 2.5, 5, 7.5, 10, 12.5, 14 µg/mL nitroreductase in the presence of 0.4 mM NADH 
in 10 mM PBS buffer (pH 7.4) containing 10% Emerald II Enhancer. 
 
 
Figure 3-5. Long-time scan of the chemiluminescence emission at 545 nm of 10 µM HyCL-2 to 
14 µg/mL nitroreductase and 0.4 mM NADH in 10 mM PBS buffer (pH 7.4) and 10% Emerald II 
Enhancer. 
 
We next evaluated the selectivity of HyCL-1 and HyCL-2 against other biologically 
relevant agents such as thiols which are well known reducing agents in our body involved in 
various redox cycles.20 HyCL-1 and HyCL-2 (10 µM) were treated with 14 µg/mL 
nitroreductase and 0.4 mM NADH, 5 mM reduced GSH, 1 mM L-cysteine and Hcy, and 200 µM 
H2S, dithiothreitol, citrate, sodium metabisulfite, and L-ascorbic acid in PBS buffer containing 
10% Emerald II Enhancer, and the luminescence responses were monitored in a time course of 
20 min. Surprisingly, HyCL-1 with the carbonate linker showed poor selectivity towards some 
(a) (b)
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thiol species such as GSH, cysteine, Hcy, and dithiothreitol (Figure 3-6a), whereas the ether 
linked HyCL-2 showed excellent selectivity, and none of the species tested displayed significant 
increases in luminescent intensity over the blank control (Figure 3-6b). Selectivity towards 
nitroreductase (14 µg/mL) or NADH (0.4 mM) was also studied. None of them induced an 
observable chemiluminescent increase, suggesting that only nitroreductase and NADH together 
can produce a luminescent response. Though H2S-mediated reduction of nitro groups to amines 
has been reported, this synthetic procedures requires a pH in the range of 10.5 to 12.21 Due to 
this requirement for elevated pH, no significant chemiluminescence emission was observed when 
treating our probes with H2S at pH 7.4, consistent with the previous report from the Pluth 
group.22 To better understand the selectivity of HyCL-1 with cellular relevant thiols and 
decipher the poor selectivity of HyCL-1, HyCL-1 was treated with cysteine and the reaction 
progress was monitored via 1H NMR (Figure 3-7). From NMR experiments, we observed that 
the methylene peak at 5.36 ppm disappeared and a new peak at 5.32 ppm formed quickly within 
5 minutes, indicating the reaction between carbonate and thiol, and the peak at 8.18 ppm and 
7.56 ppm persisted for more than 25 hours, suggesting that nitro group wasn’t reduced by thiols. 
Taken together, these results demonstrated that the ether linked HyCL-2 can be applied for 
sensitive and selective detection of reductive enzyme in vitro. 
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Figure 3-6. Chemiluminescent responses of (a) 10 µM HyCL-1 and (b) 10 µM HyCL-2 to 
biologically relevant analytes in 10 mM PBS buffer (pH 7.4) containing 10% Emerald II 
Enhancer. Bars represent chemiluminescence emission at 545 nm and 4, 8, 12, 16, 20 min after 
addition of reducing agents. Data shown are for 5 mM GSH, 1 mM cysteine and Hcy, and 200 
µM for other agents. (1) nitroreductase and NADH; (2) GSH; (3) L-cysteine; (4) Hcy; (5) 
dithiothreitol; (6) nitroreductase; (7) NADH; (8) H2S; (9) citrate; (10) Na2S2O5; (11) L-ascorbic 
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Figure 3-7. 1H NMR spectra of 8.33 mM HyCL-1 and 16.67 mM cysteine in 5:1 DMSO-
d6: D2O. (a) Full 1H NMR spectra of cysteine, HyCL-1, and 5 min and 25 hours after 
adding reagents to the NMR tube. (b) Expansion of the 1H NMR spectra from 4.5 to 6.5 
ppm of HyCL-1 and 5 min and 25 hours after adding reagents to the NMR tube. 
 
We next investigated the ability of HyCL-2 for hypoxia detection using an in vitro 
model. A solution of 10 mM PBS (pH 7.4) containing 10% Emerald II Enhancer was bubbled 
with nitrogen gas for 60 minutes to interrogate the luminescent response under low oxygen 
conditions. The mixture was transferred to a capped cuvette, and 10 µM HyCL-2, 0.4 mM 
NADH and various amounts of nitroreductase were added in a strict nitrogen protected 
atmosphere. A significant difference of chemiluminescent signal between deoxygenated solution 
and non-degassed solution was observed. Luminescence emission from the deoxygenated 
solution was 5-fold higher compared with non-degassed solution (Figure 3-8). A control 
experiment was conducted by bubbling air through a solution of 10 mM PBS (pH 7.4) containing 
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observed from the experiment conducted under ambient conditions, confirming that the increased 
signal resulted from deoxygenation and not from a mechanical effect of the bubbling procedure 
(Figure 3-9). This is surprising because the nitroreductase used in this study is oxygen-
insensitive.23 One possible explanation is that oxygen quenches the triplet state product or one of 
the radical intermediates of the chemiluminescent reaction of HyCL-2.24 Taken together, these in 
vitro experiments confirm that the oxygen level plays a significant role in chemiluminescence 
emission of HyCL-2, a necessary trait for imaging tumor hypoxia.   
 
 
Figure 3-8. Integrated chemiluminescence emission in the presence (red bars) and absence 
(green bars) of oxygen over 20 min of 10 µM HyCL-2 and 0, 5, 10, and 12.5 µg mL–1 
nitroreductase in 10 mM PBS buffer (pH 7.4) containing 0.4 mM NADH and 10% Emerald II 
Enhancer (n = 3).  Error bars are ±S.D. 
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Figure 3-9. Integrated chemiluminescence emission at 545 nm from (1) ambient, (2) oxygen 
bubbled, (3) air bubbled, or (4) N2 bubbled 10 mM PBS buffer (pH 7.4) containing 10% Emerald 
II Enhancer with 12.5 µg/mL of nitroreductase in the presence of 0.4 mM NADPH and 10 µM 
HyCL-2 integrated over 20 min. Error bars are ± S.D. 
 
Figure 3-10. Imaging of nitroreductase using HyCL-2. (a) Images 30 min after adding 10 µM 
HyCL-2 to 0, 2.5, 5, 7.5, 10, 12.5 µg/mL nitroreductase in 10 mM PBS buffer (pH 7.4) 
containing 0.4 mM NADH and 10% Emerald II Enhancer (n = 3 wells). (b) Quantification of 
total photon flux of the images in (a) (n = 3 wells). Error bars are ±S.D. 
 
Next, we applied HyCL-2 for nitroreductase imaging at physiological pH using an IVIS 
Spectrum. We added 10 µM HyCL-2, 0, 2.5, 7.5, 10, 12.5 µg/mL nitroreductase, 0.4 mM 
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light intensity clearly increased with the increasing nitroreductase (Figure 3-10a), and a linear 
response was observed (Figure 3-10b), indicating that HyCL-2 is capable of accurately and 
sensitively imaging reductase activity. The detection limit (3 s) obtained from this experiment 
was between 2–10 ng/mL. Inspired with the robust chemiluminescent light production from plate 
experiment, we proceeded to apply HyCL-2 for nitroreductase imaging in living animals. 
Anesthetized SCID/BALB-C mice were administered subcutaneous injections with 
nitroreductase and NADH on the upper side and a control without nitroreductase and NADH was 
conducted on the lower back (Figure 3-11). The upper side displayed a dramatic increase in 
chemiluminescence emission compared with vehicle control on the lower back, confirming that 
the light production from HyCL-2 was sufficient for nitroreductase imaging in living animal.  
 
 
Figure 3-11. In vivo nitroreductase imaging. (a) Image of a living SCID/BALB-C mouse 30 s 
after administering subcutaneous injections of 30 µL of a solution containing 40 µM HyCL-2, 
14 µg mL–1 nitroreductase, 0.4 mM NADH, and 10% Emerald II Enhancer in 10 mM PBS (pH 
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NaOH. (b) Quantification of biological replicates (n = 2 mice). Error bars are high and low 
values of the two replicates. 
 
After demonstrating that light production from HyCL-2 was sufficient to be observed 
through mammalian tissue, we interrogated the ability of HyCL-2 to image tissue oxygenation 
and hypoxia in human tumor xenograft models. H1299 lung tumors were planted subcutaneously 
on the flanks of SCID/BALB-C mice. Mice were treated with either air (21% oxygen) or 100% 
oxygen before imaging. After several minutes, mice were intratumorally injected with the 
HyCL-2 in PBS buffer (pH 7.4) containing 10% Emerald II Enhancer. The mice breathing air 
showed high chemiluminescent signal compared with the mice breathing pure oxygen, which can 
be attributed to the different level of tumor oxygenation (Figure 3-13). This tumor imaging 
experiment is in agreement with the in vitro experiment that low oxygenation gives high 
chemiluminescent signal. We conducted a MSOT imaging experiment to further confirm our 
results. The concentration of hemoglobin (Hb) and oxygen-bound hemoglobin (HbO2) of the 
same mice who underwent chemiluminescence imaging were evaluated by MSOT imaging13. 
The mice breathing pure oxygen displayed a clearly elevated concentration of HbO2 (Figure 3-
14). Taken together, those experiments validate that HyCL-2 is capable of imaging tissue 
oxygenation and tumor hypoxia. 
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Figure 3-12. Images of living H1299 lung tumor xenografts on SCID/BALB-C mice 1.5 min 
after administering intratumoral injections of 100 µL of a solution of 40 µM HyCL-2 and 10% 
Emerald II Enhancer in 10 mM PBS (pH 7.4) while breathing (a) air or (b) 100% oxygen. (c) 
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Figure 3-13. Multi-spectral optoacoustic tomography (MSOT) images of a living H1299 bearing 
SCID/BALB-C mouse while breathing (a) 16% oxygen or (b) 100% oxygen. Scale bars are 3 
mm. 
 
3.3 Concluding remarks 
To close, we have designed and synthesized two reaction-based chemiluminescent 
probes, HyCL-1 and HyCL-2. Both display immediate light emission upon reacting with 
nitroreductase at physiological pH. HyCL-2 gave ~170-fold chemiluminescent increase in a time 
course of 20 min with negligible background emission. Furthermore, HyCL-2 displayed superior 
selectivity towards biological relevant thiol species such as GSH and cysteine. These improved 
properties can be attributed to a more stable ether linkage. HyCL-2 has been successively 
applied for the detection and imaging of nitroreductase using an IVIS Spectrum. HyCL-2 is 
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in H1299 human tumor xenografts grown in a murine model as independently confirmed using 
optoacoustic imaging. 
3.4 Experimental section 
3.4.1 Chemical synthesis  
 
4-nitrobenzyl(2,5-dioxopyrrolidin-1-yl)carbonate (8). N,N’-Disuccinimidyl carbonate (1.253 
g, 4.89 mmol, 1.5 equiv) was added to a solution of  4-nitrobenzyl alcohol (500 mg, 3.26 mmol, 
1.0 equiv) in 10.0 mL CH2Cl2, followed directly by the addition of NEt3 (1.37 mL, 9.79 mmol, 
3.0 equiv). The reaction was stirred for 8.5 h at rt. The reaction was quenched with 20 mL 1 M 
NaHCO3, extracted with 2 x 30 mL CH2Cl2, washed with 10 mL brine, dried over Na2SO4, 
filtered, and concentrated to yield 8 (955.3 mg) as an orange oil and used without further 
purification. 1H NMR (500 MHz, CDCl3) d 8.26 (d, 2H, J = 8.6 Hz), 7.57 (d, 2H, J = 8.6 Hz), 
5.40 (s, 2H), 2.83 (s, 4H). 
 
5-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)-2-chlorophenyl(4-
nitrobenzyl)carbonate (9). Phenol 5c (235 mg, 0.77 mmol, 1.0 equiv) was dissolved in 5 mL 
4:1 THF:CH2Cl2 in a dry flask under N2 atmosphere. Mixed carbonate 8 (284 mg, 0.92 mmol, 1.2 
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NEt3 (322 µL, 2.31 mmol, 3.0 equiv) were then added in succession. After 10 h of stirring at rt, 
the mixture was poured into a separatory funnel containing 20 mL CH2Cl2 and 15 mL DI-H2O 
and extracted with 3 x 20 mL CH2Cl2. The organic layer was washed with 10 mL brine, dried 
over Na2SO4, filtered, and concentrated. Purification by silica column chromatography (1:15 
EtOAc/hexanes) afforded 9 as a clear oil (164.8 mg, 44%). 1H NMR (500 MHz, CDCl3) d 8.24 
(d, 2H, J = 8.6 Hz), 7.60 (d, 2H, J = 8.6 Hz), 7.39 (d, 1H, J = 8.0 Hz), 7.19 (m, 2H), 5.39 (s, 2H), 
3.28 (s, 3H), 3.22 (s, 1H), 2.63 (s, 1H), 1.20–2.00 (m, 12H); 13C NMR (125 MHz, CDCl3) d 
152.57, 148.09, 146.76, 141.86, 141.66, 136.03, 134.00, 130.04, 128.60, 128.45, 125.35, 124.00, 
123.74, 69.06, 58.14, 39.21, 39.08, 37.10, 32.30, 30.44, 28.24; HRMS calcd for C26H26NO6Cl 
(M+Na)+ 484.1521, found 484.1519. 
 
2-chloro-5-((1r,3r,5r,7r)-4'-methoxyspiro[adamantane-2,3'-[1,2]dioxetan]-4'yl)phenyl(4-
nitrobenzyl)carbonate (HyCL-1). Enol ether 9 (80 mg, 0.17 mmol, 1.0 equiv) and Rose bengal 
(8 mg, 0.0079 mmol, 0.046 equiv) were added into a dry flask and dissolved in 7 mL THF. 
Oxygen was bubbled through the reaction mixture, while irradiating with a 120 W light bulb 
(Home Depot, Dallas, TX) at 0 °C. After 3 h of reaction, TLC showed no starting material left 
and the mixture was then concentrated under vacuum at 0 ºC and the residue was purified by the 
silica column chromatography (1:15 EtOAc/hexanes) to deliver HyCL-1 as a white solid (68 mg, 
75%). 1H NMR (500 MHz, CDCl3) d 8.27 (d, 2H, J = 8.6 Hz), 7.61 (d, 2H, J = 8.6 Hz), 7.00–
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NMR (125 MHz, CDCl3) d 152.41, 148.17, 146.73, 141.65, 135.57, 130.45, 128.62, 128.12, 




(11). Phenol 5c (230 mg, 0.68 mmol, 1.0 equiv) and triphenylphosphine (214 mg, 0.82 mmol, 1.2 
equiv) were dissolved in anhydrous THF. Diethyl azodicarboxylate (128 µL, 0.82 mmol, 1.2 
equiv) was added dropwise over 5 min and then 4-nitrobenzyl alcohol (104 mg, 0.68 mmol, 1.0 
equiv) was added immediately. After 1 h of stirring at rt, the mixture was concentrated. 
Purification by silica column chromatography (1:12 EtOAc/hexanes) afforded 5 as a yellow oil 
(250 mg, 84 %). 1H NMR (500 MHz, CDCl3) d 8.24 (d, 2H, J = 8.6 Hz), 7.65 (d, 2H, J = 8.6 
Hz), 7.35 (d, 1H, J = 8.0 Hz), 6.91 (m, 2H), 5.25 (s, 2H), 3.26 (s, 3H), 3.21 (s, 1H), 2.54 (s, 1H), 
1.20–2.00 (m, 12H); 13C NMR (125 MHz, CDCl3) d 153.33, 147.65, 144.01, 142.42, 135.54, 
132.97, 129.97, 127.50, 123.90, 123.48, 122.21, 114.54, 69.42, 57.90, 39.23, 39.06, 37.13, 32.38, 
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(1r,3r,5r,7r)-4'-(4-chloro-3-((4-nitrobenzyl)oxy)phenyl)-4'-methoxyspiro [adamantane-2,3'-
[1,2]dioxetane] (HyCL-2). Enol ether 5 (75 mg, 0.17 mmol, 1.0 equiv) and rose bengal (8.5 mg, 
0.0084 mmol, 0.049 equiv) were added into a dry flask and dissolved in 5 mL THF. Oxygen was 
bubbled through the reaction mixture, while irradiating with a 120 W light bulb (Home Depot, 
Dallas, TX) at 0 °C. After 3 h of reaction, TLC showed no starting material left and the mixture 
was then concentrated under vacuum at 0 ºC and the residue was purified by the silica column 
chromatography (1:15 EtOAc/hexanes) to deliver HyCL-2 as a white solid (56.4 mg, 71%). 1H 
NMR (500 MHz, CDCl3) d 8.25 (d, 2H, J = 8.6 Hz), 7.67 (d, 2H, J = 8.6 Hz), 6.80–7.30 (br, 
3H), 5.34 (s, 2H), 3.24 (s, 3H), 2.98 (s, 1H), 2.06 (s, 1H), 1.00–2.00 (m, 13H); 13C NMR (125 
MHz, CDCl3) d 153.33, 147.74, 143.68, 134.98, 127.56, 124.00,  111.57, 95.57, 87.03, 69.48, 
50.04, 36.31, 34.83, 33.28, 33.17, 32.28, 31.72, 31.54, 25.97, 25.90; HRMS calcd for 
C25H26NO6Cl (M+Na)+ 494.1341, found 494.1337. 
 
3.4.2 Spectroscopic measurements 
889 µL of a 10 mM PBS buffered to pH 7.4, 2 µL of a 5 mM HyCL-1 or HyCL-2 in 
DMSO, 8 µL of a 50 mM NADH in 0.01 mM NaOH solution, 1.4 µL of nitroreductase from 
Escherichia coli  (Sigma-Aldrich, N9284-1MG) in DI-H2O (1 mg nitroreductase dissolved in 
100 µL DI-H2O, 10 mg/mL), and 100 µL Emerald II Enhancer were added to an Eppendorf tube 
and samples were shaken gently to assure mixing. The mixed solution was then transferred to a 
quartz cuvette. Time scans were acquired using the time scan module 1 min after adding probes. 
For the dose-dependent response to nitroreductase, 10 µM HyCL-1 and HyCL-2 were treated 
with 8 µL of a 50 mM NADH and 0, 0.5, 0.75, 1.0, 1.25, 1.4 µL 10 mg/mL nitroreductase and 20 
min or 120 min scans were measured 1 min after adding probes. Selectivity for HyCL-1 and 
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HyCL-2 was measured by monitoring the time-dependent chemiluminescence emission at 545 
nm. All assays were performed in 10 mM PBS buffered to pH 7.4 with 10% Emerald II 
Enhancer.  
Nitroreductase (14 µg/mL) and NADH (0.4 mM): 889 µL of a 10 mM PBS buffer (pH 7.4), 2 µL 
of 5 mM HyCL-1 or HyCL-2 in DMSO, 8 µL of 50 mM NADH in 0.01 mM NaOH, 1.4 µL of 
10 mg/mL nitroreductase, and 100 µL Emerald II Enhancer were added to an Eppendorf tube and 
was shaken gently to assure mixing. The mixed solution was then transferred to a quartz cuvette.  
GSH (5 mM): 50 µL of a 100 mM stock solution of GSH in DI-H2O was added to a solution of 
848 µL 10 mM PBS buffer (pH 7.4) and 2 µL of 5 mM HyCL-1 or HyCL-2 in DMSO and then 
100 µL Emerald II Enhancer was added into this mixture in an Eppendorf tube and then 
transferred to a quartz cuvette. 
L-Cysteine (1 mM): 10 µL of a 100 mM stock solution of L-cysteine in DI-H2O was added to a 
solution of 888 µL 10 mM PBS buffer (pH 7.4) and 2 µL of 5 mM HyCL-1 or HyCL-2 in 
DMSO and then 100 µL Emerald II Enhancer was added into this mixture in an Eppendorf tube 
and then transferred to a quartz cuvette. 
Hcy (1 mM): 10 µL of a 100 mM stock solution of Hcy in DI-H2O was added to a solution of 
888 µL 10 mM PBS buffer (pH 7.4) and 2 µL of 5 mM HyCL-1 or HyCL-2 in DMSO and then 
100 µL Emerald II Enhancer was added into this mixture in an Eppendorf tube and then 
transferred to a quartz cuvette. 
Dithiothreitol (200 µM): 2 µL of a 100 mM stock solution of dithiothreitol in DI-H2O was added 
to a solution of 896 µL 10 mM PBS buffer (pH 7.4) and 2 µL of 5 mM HyCL-1 or HyCL-2 in 
DMSO and then 100 µL Emerald II Enhancer was added into this mixture in an Eppendorf tube 
and then transferred to a quartz cuvette. 
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NADH (0.4 mM): 890 µL of a 10 mM PBS buffer (pH 7.4), 2 µL of a 5 mM HyCL-1 and 
HyCL-2 in DMSO, 8 µL of a 50 mM NADH, and 100 µL Emerald II Enhancer were added to an 
Eppendorf tube and was shaken gently to assure mixing. The mixed solution was then transferred 
to a quartz cuvette. 
Nitroreductase (14 µg/mL): 897 µL of a 10 mM PBS buffer (pH 7.4), 2 µL of a 5 mM HyCL-1 
or HyCL-2 in DMSO, 1.4 µL of nitroreductase, and 100 µL Emerald II Enhancer were added to 
an Eppendorf tube and was shaken gently to assure mixing. The mixed solution was then 
transferred to a quartz cuvette. 
H2S (200 µM): 10 µL of a 20 mM stock solution of Na2S in DI-H2O was added to a solution of 
888 µL 10 mM PBS buffer (pH 7.4) and 2 µL of 5 mM HyCL-1 or HyCL-2 in DMSO and then 
100 µL Emerald II Enhancer was added into this mixture in an Eppendorf tube and then 
transferred to a quartz cuvette. 
Sodium Citrate (200 µM): 2 µL of a 100 mM stock solution of sodium citrate in DI-H2O was 
added to a solution of 896 µL 10 mM PBS buffer (pH 7.4) and 2 µL of 5 mM HyCL-1 and 
HyCL-2 in DMSO and then 100 µL Emerald II Enhancer was added into this mixture in an 
Eppendorf tube and then transferred to a quartz cuvette. 
Na2S2O5 (200 µM): 2 µL of a 100 mM stock solution of Na2S2O5 in DI-H2O was added to a 
solution of 896 µL 10 mM PBS buffer (pH 7.4) and 2 µL of 5 mM HyCL-1 or HyCL-2 in 
DMSO and then 100 µL Emerald II Enhancer was added into this mixture in an Eppendorf tube 
and then transferred to a quartz cuvette. 
L-ascorbic acid (200 µM): 2 µL of a 100 mM stock solution of L-ascorbic acid in DI-H2O was 
added to a solution of 896 µL 10 mM PBS buffer (pH 7.4) and 2 µL of 5 mM HyCL-1 or 
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HyCL-2 in DMSO and then 100 µL Emerald II Enhancer was added into this mixture in an 
Eppendorf tube and then transferred to a quartz cuvette. 
Blank: 2 µL of 5 mM HyCL-1 or HyCL-2 in DMSO was added to a solution of 898 µL 10 mM 
PBS buffer (pH 7.4) and then 100 µL Emerald II Enhancer was added. 
 
3.4.3 GC-MS analysis of the reaction of HyCL-2 with nitroreductase 
2966 µL of a 10 mM PBS buffer (pH 7.4), 6 µL of 10 mM HyCL-2 in DMSO, 24 µL of 
50 mM NADH in 0.01 mM NaOH, 4 µL of 10 mg/mL nitroreductase were added into a vial, 
mixed well. Then After 3 h of incubation at rt, the mixture was poured into a separatory funnel 
containing 10 mL CH2Cl2 and 15 mL DI-H2O and extracted with 3 x 10 mL CH2Cl2. The organic 
layer was collected, dried over Na2SO4, filtered, and concentrated. Then the solid was re-
dissolved in 2 mL CH2Cl2, transferred to a GC-MS vial and GC-MS was conducted immediately 
using a 6850 Series GC-MS (Agilent Technologies, Santa Clara, CA). As a control experiment, 
the same procedure was conducted except that HyCL-2 was replaced with 6 µL DMSO. Mass 
spectra were averaged across the peak found in the extracted ion chromatogram for m/z = 186 
(Figure S2-1), m/z = 150 (Figure S2-2), and m/z = 121 (Figure S2-3). Matches to the NIST 
database were found using the NIST Mass Spectral Search Program for the NIST/EPA/NIH 
Mass Spectral Library Version 2.0 d, build Dec 2, 2005 installed with the Enhanced Chemstation 
software.  
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Figure 3-14. Mass spectrum found for m/z = 186. Inserted is the mass spectra found by NIST 
Mass Spectral Search Program. 
 
 
Figure 3-15. Mass spectrum found for m/z = 150. Inserted is the mass spectra found by NIST 
Mass Spectral Search Program. 
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Figure 3-16. Mass spectrum found for m/z = 121.  
 
3.4.4 Monitoring reaction of HyCL-1 and nitroreductase by 1H NMR 
500 µL of 10 mM HyCL-1 in DMSO-d6 and 100 µL of 100 mM cysteine in D2O were 
mixed well in an Eppendorf tube and then transferred to an NMR tube. The reaction progress 
was monitored by 1H NMR at 500 MHz. 
 
3.4.5 In vitro deoxygenation experiments 
10 mM PBS buffer (pH 7.4) and Emerald II Enhancer were mixed with a ratio of 9 to 1 
and N2, air or 100% O2 was bubbled through it for 60 minutes. The solution was then transferred 
into a capped cuvette by syringe, and later HyCL-2, NADH and nitroreductase were added into 
the cuvette using a syringe. Time scans were performed 1 min after adding nitroreductase. For 
deoxygenation experiments, PBS buffer (pH 7.4) and Emerald II Enhancer mixture was 
deoxygenated by bubbling N2 for 60 minutes, and then 889 µL of this deoxygenated mixture was 
transferred into a capped cuvette by syringe, and later 2 µL of a 5 mM HyCL-2 in DMSO, 8 µL 
 
NHO
  97 
of a 50 mM NADH in 0.01 mM NaOH solution, 1.25 µL of nitroreductase (10 mg/mL) were 
added into the cuvette using syringe. Time scans were performed 1 min after adding 
nitroreductase. The control experiment was carried out under ambient conditions without 
deoxygenation. 
 
3.4.6 In vitro chemiluminescence imaging 
Imaging was carried out with a Caliper Xenogen IVISÒ Spectrum in black 96-well 
CostarÒ plates and all the images were analyzed using Living Image 3.1 software. 1 mM HyCL-
2 in DMSO, 2 mg/mL nitroreductase (10 µL from 1 mg nitroreductase /100 uL DI-H2O diluted 
to 50 µL by adding 40 µL DI-H2O) and 50 mM NADH in 0.01 mM NaOH solution were 
prepared prior to imaging. 176.4 µL, 176.1 µL, 175.9 µL, 175.5 µL 175.4 µL and 175.1 µL of 10 
mM PBS buffer (pH 7.4) were added into wells from A1 to A6 in sequence, 1.6 µL NADH was 
pipetted into each well and then different volume of nitroreductase solution (0 µL, 0.25 µL, 0.5 
µL, 0.75 µL, 1.0µL, 1.25 µL) were added into each well. 2 µL HyCL-2 was added into the 
mixture and 20 µL Emerald II Enhancer was pipetted into each well, and imaging was performed 
3.45 minutes after starting adding reagent into 96 well plate using an open filter. All images were 
acquired with f-stop 1, medium binning, auto exposure and the chamber set to 37 °C. The 
detection limit was determined from the linear plot of nitroreductase concentration versus total 
photon flux as the amount of nitroreductase required to give a chemiluminescent signal above 
three times the standard deviation of at least 3 independent experiments with 0 µg/mL 
nitroreductase. These provided detection limits of 9.6 ng/mL with measurements taken 30 second 
after reagent addition and 1.9 ng/mL with measurements taken 30 min after reagent addition. 
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3.4.7 General animal protocols 
The UT Southwestern Institutional Animal Care and Use Committee approved these 
investigations under Animal Protocol Number (APN #2009-0150). Hair was removed from area 
surrounding the tumor using Nair (Church & Dwight Co, Inc, Ewing, NJ), but the skin was left 
unbroken before injection. Mice were anesthetized and maintained using inhalation of 1.6% 
isoflurane in 16% oxygen gas.  
 
3.4.8 In vivo CLI of nitroreductase 
A stock solution of 5 mM HyCL-2 in DMSO, 1 mg nitroreductase dissolved in 100 µL 
DI-H2O and 50 mM NADH in 0.01 mM NaOH solution were prepared in advance. A 30 µL 
aliquot of this solution was taken out from a mixture of 437 µL 10 mM PBS, 4 µL HyCL-2, 8 
µL NADH, 1.25 µL nitroredctase and 50 µL Emerald II Enhancer and images were acquired 30 
second after administering i.p. injections to anesthetized (1.6% isoflurane) SCID/BALB-C mice. 
A vehicle control was conducted in the same way except replacing nitroreductase and NADH 
with H2O and 0.01 M NaOH, respectively. 
In vivo CLI of hypoxia in tumor xenografts. 100 µL solution was taken out from a mixture of 
446 µL of 10 mM PBS, 50 µL Emerald II Enhancer and 4 µL of a 5 mM solution of HyCL-2 
and images were acquired immediately and every minute after administering intratumoral 
injections to H1299 lung tumor xenografts on mice while the animals breathed ambient air. A 
similar experiment was performed in the same mice, but while breathing 100% oxygen 5 minutes 
before injection and throughout the course of the imaging experiment. These experiments were 
reproduced on two different mice (n = 2). Tumor sizes were 9.9 mm x 6.4 mm x 5.5 mm and 9.5 
mm x 7.6 mm x 6.0 mm. 
  99 
Multispectral optoacoustic tomography (MSOT). A thin layer of ultrasound coupling gel 
provided contact with the membrane and the animal holder was placed in the imaging chamber 
of the MSOT 256-TF device (iThera Medical Gmbh, Munich, Germany). Multi-spectral 
optoacoustic tomography (MSOT) imaging was performed in a transaxial section through the 
center of the tumor using five wavelengths:  715, 730, 760, 800, and 850 nm. Twenty frames per 
wavelength were acquired and averaged.  Initially, the tumor region was imaged while breathing 
16% oxygen, which was switched to 100% oxygen. A model-based reconstruction was used 
prior to multispectral processing to provide relative concentrations of oxyhemoglobin and 
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CHAPTER 4 
A CHEMILUMINESCENT PROBE FOR CELLULAR PEROXYNITRITE USING A SELF-
IMMOLATIVE OXIDATIVE DECARBONYLATION REACTION 
 
4.1 Introduction 
Peroxynitrite (ONOO−) is a strong reactive oxygen species that can be formed 
biologically from a fast reaction between superoxide radical anion (O2•−) and nitric oxide (NO•).1 
ONOO– and its protonated species, ONOOH (pKa 6.8) coexist under physiological conditions. 
There are two distinct pathways for ONOO– involved oxidation. ONOO– can oxidize target 
molecules directly through one- or two-electron reactions. The most notable functional groups 
involved in this chemistry are thiols. 2 The more robust oxidative modifications are mediated by 
the radicals from its decomposition. The protonated ONOOH decomposes to form nitrogen 
dioxide (NO2•) and hydroxyl (OH•) radicals via homolysis of the O–O bond. ONOO– can be 
consumed rapidly by CO2,3 to form ONOOCO2– which decomposes into carbonate radical 
(CO3•−), and nitrogen dioxide (NO2•) (Scheme 4-1). Due to the abundance of CO2 in living 
system, and the fast reactivity, this represents a major pathway for radical generation. These 
radicals together can mediate a lot of oxidative transformations of biomolecules. 
  104 
 
Scheme 4-1. The generation of ONOO− and its decomposition pathways. 
 
With its strong oxidative properties and the propensity of generating radicals upon 
decomposition, ONOO− has long been recognized as a toxic agent, highly associated with 
oxidative damage and destruction of biomolecules, such as lipids, proteins, and nucleic acids.4 
Upregulation of ONOO− was believed to disrupt cellular processes and signaling pathways and 
contribute to diseases such as  ischemia-reperfusion,5 diabetes6, cardiac dysfunction,7 
inflammatory conditions,8 and autoimmune9 and neurodegenerative diseases.10 Recently, 
ONOO– has been recognized to play some beneficial roles in certain conditions, such as in the 
immune system11 and ischemic preconditioning.12 ONOO– can be generated in the immune 
activation process to attack invading pathogens.13 The main challenge in revealing its detailed 
biological roles and differentiating its oxidative damage from its beneficial effects lie in the 
difficulty of direct monitoring its generation and distribution in living systems. Therefore, the 
development of new methods and probes for ONOO– is crucial for better understanding its 
biological functions. 
Nitrotyrosine has been used previously as a biomarker for indirect measurement of 
ONOO–,14 but lacks temporal precision and can’t provide direct information on ONOO–. Optical 
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living systems during last three decades and scientists are thrilled about “seeing” biological 
systems using imaging agents. A myriad of reaction-based fluorescent probes has been reported 
for ONOO−. These imaging agents can be tuned for the selective detection of ONOO– through 
unique transformations to display an optical change such as the intensity or the wavelength, and 
many of them have been successfully applied for biological studies in living cells or animals, 
such as trifluorocarbonyl-based15, N-dearylation-based,16 boronic ester-based.17  Among them, 
organoselenium-based,18 and organotellurium-based19 probes can be used for monitoring the 
reversible cycle of the oxidative stress. However, these fluorescent probes have some 
disadvantages associated with this imaging modality, such as photoscattering, autofluorescence 
and photobleaching. 
In light of the unique advantages of chemiluminescent probes owing to the elimination of 
excitation light, we and others have previously used chemiluminescence as an imaging modality 
for designing reaction-based chemiluminescent probes for cellular and live animal imaging.20, 21–
25   Schaap’s adamantylidene-dioxetane scaffold was adopted by tethering a target responsive 
functionality for a specific analyte. Chemiluminescence can only be triggered by removal of the 
functional group by the analyte of interest. Although this design strategy is promising for 
constructing chemiluminescent agents for a variety of reactive species in living systems, the light 
production isn’t sufficient, which requires the addition of polymeric enhancer solutions to 
amplify light emission. Shabat and coworkers have proposed a new molecular methodology to 
obtain highly emissive chemiluminescent probes by introducing an electron withdrawing group 
such as an acrylonitrile at the ortho-position of the phenol.26 As a result, chemiluminescence 
emission can be observed in aqueous conditions without the addition of enhancer. 
Chemiluminescent probes for ONOO– detection have been reported by using nanoparticle-based 
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methods27 which respond to the downstream decomposition products HO• and O2•– to provide an 
indirect measurement of ONOO–. In order to expand the toolbox for ONOO– detection and create 
a chemiluminescent probe for direct ONOO– measurement, we report the development and 
application of a chemiluminescent probe for the detection of ONOO–, PNCL, with both in vitro 
and live cell applications.  
 
4.2 Results and discussion 
4.2.1 Design and synthesis of PNCL 
  Our lab is interested in developing new imaging agents for interrogating the biological 
functions of RSON28,29,30 species. We have previously reported that isatin reacts selectively with 
ONOO– through an oxidative decarbonylation reaction to generate anthranilic acid.31 19F NMR 
probes, 5-fluoroisatin and 6-fluorisatin, have been developed for selective detection of ONOO– 
based on this discovery. Initial attempts to expand the toolbox for ONOO– detection centered 
around the preparation of N-aryl isatin derivatives, anticipating a photophysical change upon 
reacting with ONOO–. However, these attempts didn’t work out the way as we expected. 
Mechanistic explorations were conducted to elucidate the structural necessity of this selective 
transformation. We treated isatin and its derivatives (Figure 4-1A) with SIN-1 (ONOO– donor), 
revealing that fluorescent emission from N-phenyl isatin and a dimethyl acetal derivative was 
significantly decreased. This important experiment demonstrated that the ketone and NH sites 
are essential in maintaining the selective reactivity between isatin and ONOO–.  
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Figure 4-1. Mechanistic and structure-activity studies. (a) Fluorescence emission intensity at 400 
nm of 50 µM isatin and 200 µM SIN-1. (b) Fluorescence emission intensity at 400 nm of 200 
µM ONOO– and 50 µM of isatin derivatives. Legend: 1. isatin, 2. N-methyl isatin, 3. N-phenyl 
isatin, 4. isatin dimethyl acetal. (c) Fluorescence emission intensity at 400 nm of 50 µM isatin, 
200 µM ONOO–, and 0–5 mM NaHCO3. (d) Fluorescence emission intensity at 400 nm of 50 
µM isatin, 200 µM ONOO–, and 0–5 mM TEMPOL. All experiments were performed in 20 mM 
HEPES (pH 7.4), containing 1% DMSO with excitation wavelength at 320 nm. (Data was 
collected by Audrey Reeves) 
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To rule out the reactivity between isatin and downstream radicals generated by ONOO−, 
such as HO•, CO3•– and NO2•, we performed a series of competition experiments. These results 
showed that the radical scavenger, TEMPOL, didn’t interfere with the reaction between isatin 
and ONOO–, while NaHCO3, which equilibrates with CO2 in solution, inhibited the reaction 
(Figure 4-1C,D) since ONOO– can rapidly react with CO2. These inhibitor experiments further 
supported that isatin reacted directly with ONOO– instead of its downstream radicals. One 
possible mechanism was proposed based on these studies (Scheme 4-2). These mechanistic 
studies also promoted us to adopt isatin as a self-immolative functionality for making a 
chemiluminescent probe for ONOO–. The design strategy relies on tethering the isatin moiety to 
a 1,2-dioxetane chemiluminescent scaffold using an ether linkage (Scheme 4-3). The isatin reacts 
with ONOO– to generate the anthranilic acid, followed by a self-immolative 1,6-elimination to 
trigger the chemiluminescence emission through CIEEL. Synthesis of the PeroxyNitrite 
ChemiLuminescent probe (PNCL) started with the protection of the ketone group of 5-
iodoisation 12 with dimethylacetal 13 (Scheme 4-4). A reductive formylation was conducted 
with palladium acetate as catalyst and N-formyl saccharin as the CO source to convert the 
dimethylacetal 13 to the aldehyde 14.32 The aldehyde 14 was subjected to the reduction with 
NaBH4, followed by deprotection to deliver isatin alcohol 15. Next, a Mitsunobu reaction was 
performed for the preparation of the precursor 17. Finally, [2+2] cycloaddition was conducted 
using Rose bengal as a photosensitizer by bubbling oxygen into the reaction mixture with light 
irradiation to provide the 1,2-dioxetane PNCL. 
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Scheme 4-4. Synthesis of PNCL. 
 
4.2.2 Response and selectivity of PNCL to ONOO− 
After obtaining PNCL, we starteded to collect its photophysical properties and test its 
reactivity towards ONOO–. Chemiluminescence emission was obtained by treating 20 µM 
PNCL with various amounts of ONOO– without enhancer. The luminescence emission at 525 
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linearity in the range of 0–200 µM ONOO– (Figure 4-2A,C). Although PNCL was tested in 
enhancer free conditions, the luminescent intensity was comparable with CHS-3 and HyCL-2, 
which were tested in the presence of Emerald II Enhancer. A dose dependent manner of the 
chemiluminescent intensity was also observed in the time scan test (Figure 4-2B), indicating our 
probe can detect ONOO– with high sensitivity. Chemiluminescence emission reached a 
maximum immediately after adding ONOO– and was slowly decayed over a time course of 20 
min, demonstrating an advantage of this imaging modality for quick detection without extensive 
incubation. Surprisingly, the luminescent intensity of PNCL can be recovered after several 
cycles of ONOO– (Figure 4-3). This reversible property of chemiluminescent probe can be 
applied for monitoring ONOO– fluxes over time. The detection limit of PNCL was 6 nM (Figure 
4-4), comparing favorably to most reported fluorescent and chemiluminescent probes (Table 4-
1). The reaction between PNCL and ONOO– was further confirmed by GC-MS (Figure 4-5). 
The reactivity of PNCL towards SIN-1was also evaluated (Figure 4-2D), demonstrating the 
ability of PNCL to monitor the slow release of ONOO–. SIN-1 generates ONOO– by 
simultaneously generating NO• and O2•– (Scheme 4-5).33 
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Scheme 4-5. SIN-1 generates ONOO– by simultaneously generating NO• and O2•–. 
 
 
Figure 4-2. Response of PNCL to ONOO–. (A) Chemiluminescence emission spectra of 20 µM 
PNCL and 0 (blue trace), 5, 10, 20, 40, 80, 100, 200 µM (red trace) ONOO–. (B) Time scans of 
the chemiluminescence emission at 525 nm of 20 µM PNCL and 0 (blue trace), 5, 10, 20, 40, 80, 
100, 200 µM (red trace) ONOO–. (C) Peak emission intensity at 525 nm of 20 µM PNCL after 
adding 0–200 µM ONOO–. (D) Time scan of the chemiluminescence emission at 525 nm of 20 
µM PNCL and 200 µM SIN-1. All experiments were performed in 20 mM HEPES (pH 7.4), 
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Figure 4-3. Repeatability of chemiluminescent response. Time course of the chemiluminescence 
emission at 525 nm of 20 µM PNCL and 200 µM ONOO– in 20 mM HEPES (pH 7.4). Every 20 
min, an additional 200 µM ONOO– was added to the solution. 
 
 
Figure 4-4. Detection Limit of PNCL for bolus ONOO–. Integrated chemiluminescence 
emission intensity of 20 µM PNCL and 0 µM, 0.5 µM, 1 µM, 1.5 µM, and 2 µM of ONOO–. 
 
Table 4-1. Detection limits of selected fluorescent and chemiluminescent ONOO– probes. 
Reference Method LoD 
34 Fluorescence 2.5 µM 
35 Fluorescence 0.917 µM 
36 Chemiluminescence 0.1 µM 
37 Fluorescence 50 nM 
38 Fluorescence 35 nM 
39 Fluorescence 10 nM 
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this work Chemiluminescence 6 nM 
27(b) Chemiluminescence 5 nM 
40 Fluorescence 4 nM 
 
 
Figure 4-5. The reaction products were observed between PNCL and ONOO– by GC-MS. (A) 
m/z = 237, (B) m/z = 150.1. 
 
We proceeded to evaluate the selectivity of PNCL for ONOO− against other biologically 








  114 
(20 µM) with different amount of RSON species and metal cations in HEPES buffer (20 mM, pH 
7.4). 5 mM GSH, 1 mM L-cysteine, or 200 µM other reactive species and metal cations were 
used for evaluation. Most of the other species displayed negligible chemiluminescent increase 
over the blank control within 20 min (Figure 4-6). However, Angeli’s salt, a nitroxyl (HNO) 
donor, displayed a small luminescent increase. This was also observed from our previous 19F 
NMR probes.31  
 
 
Figure 4-6. Selectivity of PNCL versus reactive sulfur, oxygen, and nitrogen species. 
Chemiluminescence emission at 525 nm of 20 µM PNCL and 200 µM biologically relevant 
analytes in 20 mM HEPES (pH 7.4). Bars represent chemiluminescence emission at 525 nm at 4, 
8, 12, 16, 20 min after addition of reactive species. Legend: 1. ONOO–, 2. Cys, 3. DEA 
NONOate, 4. GSH (5 mM), 5. GSNO, 6. H2O2, 7. Angeli's salt, 8. KO2, 9. Na2S, 10. Na2SO3, 11. 
Na2SO4, 12. NaNO2, 13. HO•, 14. OCl–, 15 tBuOOH. 16. 1O2, 17. Na+, 18. Mg2+, 19. K+, 20. 
Ca2+, 21. Zn2+, 21. Fe2+, Blank. Error bars are + S.D. All experiments were performed in 20 mM 
HEPES (pH 7.4), containing <1% DMSO. (Data was collected by me and Weiwei An) 
 
In light of previous reports that HNO reacts with molecular oxygen to form ONOO− at 
physiological pH,41 and different reactivities of these two species, we designed a series of 
competition experiments to reveal what caused this luminescent increase. It is known that 
ONOO−  reacts rapidly with CO2, but slowly with GSH. However, HNO preferentially reacts 
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ONOO– (200 µM) or Angeli’s salt (200 µM) in the presence of various concentration of HCO3– 
(Figure 4-7) and GSH (Figure 4-8). Chemiluminescent intensity was decreased for both reactions 
with HCO3− addition, while GSH only quenched the chemiluminescence emission from Angeli’s 
salt. Interestingly, chemiluminescence emission relapsed after a certain amount time when less 
than 200 µM GSH was added (Figure 4-8C). This observation is consistent with the facts that 
GSH functions as the HNO scavenger at physiological condition and Angeli's salt releases HNO 
with a half-life of 2.3 minutes at 37 °C. Once the GSH was fully consumed, newly released HNO 
from Angeli’s salt can be oxidized to ONOO– to produce a luminescent increase. 
 
 
Figure 4-7. Inhibition of response by NaHCO3. (a) Time scans and (b) integrated intensity of the 
chemiluminescence emission of 20 µM PNCL, 200 µM ONOO– and 0 (blue trace), 1 mM, 2 
mM, 3 mM, 4 mM, and 5 mM (red trace) NaHCO3. (c) Time scans and (d) integrated intensity of 
the chemiluminescence emission of 20 µM PNCL, 200 µM Angeli's salt and 0 (blue trace), 1 
mM, 2 mM, 3 mM, 4 mM, and 5 mM (red trace) NaHCO3. All experiments were performed in 
20 mM HEPES (pH 7.4), containing <1% DMSO. (Data was collected by Weiwei An) 
A B
C D
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Figure 4-8. Inhibition of response by GSH. (a) Time scans and (b) integrated intensity of the 
chemiluminescence emission of 20 µM PNCL, 200 µM ONOO– and 0 (blue trace), 50 µM, 100 
µM, 200 µM, and 1 mM (red trace) GSH. (c) Time scans and (d) integrated intensity of the 
chemiluminescence emission of 20 µM PNCL, 200 µM Angeli's salt and 0 (blue trace), 50 µM, 
100 µM, 200 µM, and 1 mM (red trace) GSH. All experiments were performed in 20 mM 
HEPES (pH 7.4), containing <1% DMSO. (Data was collected by Weiwei An) 
 
We also prepared a fluorescent nitroxyl (HNO) probe, XF143,44 (Figure 4-9A), to 
determine the quenching effect of CO2 to HNO. XF1 reacts with Angeli’s salt (Figure 4-10 A,B) 
with a strong fluorescent increase, and XF1 showed good selectivity to HNO from other RSON 
species (Figure 4-10C).The fluorescence response of XF1 towards Angeli’s salt was completely 
aborted with 200 µM GSH (Figure 4-9B,C), while no significant fluorescence change was 
observed from NaHCO3 treated solution (Figure 4-9B,C), confirming that GSH quenches HNO 
but HCO3–/CO2 does not scavenge HNO. Taken together, these results indicate the formation of 
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Figure 4-9. HNO scavenging by NaHCO3 and GSH. (a) Design of XF1, a fluorescent probe for 
HNO. (b) Peak emission intensity of 10 µM XF1, 200 µM Angeli's salt and 0-5 mM NaHCO3. 
(c) Peak emission intensity of 10 µM XF1, 200 µM Angeli's salt and 0-1 mM GSH. All 
experiments were performed in 20 mM HEPES (pH 7.4), containing <1% DMSO with lex = 488 
nm. (Data was collected by Audrey Reeves) 
 
 
Figure 4-10. (a) Fluorescence emission of 10 µM XF1 and 200 µM Angeli's salt after reacting 
for 1, 5, 10, 15, 20, 25, and 30 min in 20 mM HEPES (pH 7.42). (b) Peak emission intensity of 
10 µM XF1 and 200 µM Angeli's salt after reacting for 1, 5, 10, 15, 20, 25, and 30 min in 20 mM 
HEPES (pH 7.42). (c) Selectivity of XF1 versus other reactive sulfur, oxygen, and nitrogen 
species. Legend: 1. Angeli's salt, 2. Na2S, 3. ONOO–, 4. ClO–, 5. H2O2, 6. GSH (5 mM), 7. 
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The depth of tissue penetration of PNCL and its 1,2-dioxetane phenol was determined 
using IVIS Spectrum. We used the beef bologna (Tom Thumb) as a tissue phantom to mimic the 
biological tissue and the depth was measured by ruler. The data showed that the 
chemiluminescent light from 1 mM 1,2-dioxetane phenol in basic conditions (2 mM NaOH) can 
penetrate up to 2–2.5 cm beef bologna. Furthermore, light from 1 mM PNCL and 2 mM ONOO– 
can still be visualized through up to 1.5–2 cm beef bologna (Figure 4-11). This experiment 
demonstrates that chemiluminescence as an imaging modality has great potential to explore 
biological processes in deep tissue. 
 
 
Figure 4-11. Tissue penetration of chemiluminescence of (A) 1,2-dioxetane phenol and (B) 
PNCL. Beef bologna was used to mimic tissue sample, and the depth was determined with ruler. 
 
4.2.3 Using PNCL for ONOO– detection in living cells 
PNCL reacts with ONOO–  with high sensitivity and selectivity, and the luminescent 
intensity was strong enough without the addition of a polymeric enhancer solution, which could 
potentially open a gate for ONOO– detection in living cells. A BioTek Cytation 5 plate reader 
was used for cell experiments. We first evaluated the cell toxicity of PNCL by the MTT assay. 
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Data confirmed that PNCL exhibits low toxicity at concentrations less then 100 µM and more 
than 50% cell survived with 1 mM PNCL for 24-hour incubation (Figure 4-12). Cell 
permeability was evaluated by imaging the intrinsic fluorescence emission of PNCL using an 
EVOS microscope, demonstrating good cell permeability (Figure 4-13). We next determined the 
ability of PNCL to detect ONOO– delivered from donor compound, SIN-1. RAW 264.7 
macrophages were incubated with 20 µM PNCL for 30 minutes in Dulbecco’s Modified Eagle 
Medium (DMEM), and then washed twice with PBS to remove excess probe. Luminescence 
emission was monitored by a plate reader for 8 hours after the addition of 0, 200 µM, 400 µM, 
800 µM, 1 mM, or 2 mM SIN-1. A dose dependent luminescent increase was observed and the 
signal reached a maximum at 40 minutes (Figure 4-15A,B), resulting a ~5-fold luminescent 
increase with 2 mM SIN-1 over a blank control. Similar result was obtained in A549 cells 
(Figure 4-14), demonstrating that PNCL can be used for different cell lines. Chemiluminescence 
emission was decreased by Mn(III)TMPyP, a ONOO– scavenger (Figure 4-15), confirming that 
the increased signal was from ONOO–. 
 
 
Figure 4-12. MTT assay of RAW264.7 macrophage cells in the presence of different 
concentrations of PNCL. Error bars are ±S.D. (n = 3). 
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Figure 4-13. Cellular internalization of PNCL. Normalized fluorescence (A) excitation and (B) 
emission spectrum of PNCL in 20 mM HEPES (pH 7.4). Confocal fluorescence images of living 
RAW 264.7 cells in (C) the absence of PNCL or (D) presence of 40 µM PNCL. 
 
 
Figure 4-14. ONOO– detection in A549 cells. (A) Time scans and (B) integrated intensity of 
chemiluminescence emission of A549 cells incubated with 20 µM PNCL for 30 minutes, washed 
and then treated with 0 (blue trace), 200 µM, 400 µM, 800 µM, 1 mM, and 2 mM (red trace) 
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Figure 4-15. Inhibition of signal from SIN-1 by ONOO– scavenger MnTMPyP. (A) Time scans 
of RAW 264.7 macrophages incubated with 20 µM PNCL for 30 minutes, washed, and then 
incubated with (blue trace) vehicle control (DMSO), (red trace) 2 mM SIN-1, or (black trace) 2 
mM SIN-1 and 50 µM Mn(III)TMPyP. (B) Integrated intensity of chemiluminescence emission 
of RAW 264.7 macrophages incubated with 20 µM PNCL for 30 minutes, washed, and then 
incubated with vehicle control, 2 mM SIN-1, 2 mM SIN-1 and 25 µM MnTMPyP, or 2 mM SIN-
1 and 50 µM MnTMPyP. Error bars are S.D. from n = 3 wells. Statistical significance was 
assessed using a two-tailed student's t-test. *** p < 0.001. 
 
Finally, we determined the ability of PNCL to detect endogenously generated ONOO– in 
macrophages with lipopolysaccharide (LPS) stimulation. LPS is a characteristic component of 
the bacterial cell wall and can be used to model the pathogen attack to stimulate an immune 
response of macrophages. LPS activates the immune response by interacting with the membrane 
receptors, subsequently activating a cascade of signal transductions, resulting in the high 
expression of inducible nitric oxide synthase (iNOS), followed by the generation of ONOO– 
(Scheme 4-6).45 Data showed that macrophages with 1000 ng mL–1 LPS treatment displayed 
~36% increase in integrated luminescence intensity (Figure 4-16C), and the increased signal was 
attenuated after the addition of Mn(III)TMPyP, confirming the increased signal from PNCL 
resulted from newly generated ONOO–. Chemiluminescent signal was also decreased after the 
addition of iNOS inhibitor 1400W (Figure 4-17), indicating iNOS is essential for the 
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Figure 4-16. ONOO– detection in RAW 264.7 macrophages. (a) Time scans and (b) integrated 
intensity of chemiluminescence emission of RAW 264.7 macrophages incubated with PNCL for 
30 minutes, washed and then treated with 0 (blue trace), 200 µM, 400 µM, 800 µM, 1 mM, and 2 
mM (red trace) SIN-1. (c) RAW 264.7 macrophages stimulated with (Cont) DI-H2O as a vehicle 
control, (LPS) 1000 ng mL–1 LPS, or (LPS, MnTMPyP) 1000 ng mL–1 LPS and 25 µM 
Mn(III)TMPyP. (d) Brightfield images of stimulated RAW 264.7 macrophages. Error bars are 
S.D. from n = 3–7 wells and 3 biological replicates (n = 10 wells from 6 biological replicates for 
the control experiment). Statistical significance was assessed using a two-tailed student's t-test. 
** p < 0.001, * p < 0.01. 
 
 
Figure 4-17. Inhibition of iNOS mediated ONOO– production. (A) Time scans of RAW 264.7 
macrophages incubated with (blue trace) vehicle control (DI-H2O), (red trace) 1000 ng/mL LPS, 
or (black trace) 1000 ng/mL LPS and 200 µM 1400W for 16 hours, then incubated with 20 µM 
PNCL and vehicle control or 1400W for 30 minutes, washed and measured. (B) Integrated 
intensity of chemiluminescence emission of RAW 264.7 macrophages incubated with vehicle 
control, 1000 ng/mL LPS, or 1000 ng/mL LPS and 200 µM 1400W for 16 hours, then incubated 






  124 
bars are S.D. from n = 3 wells. Statistical significance was assessed using a two-tailed student's t-
test. *** p < 0.001, * p < 0.05. 
 
4.3 Conclusions 
To close, we have designed and synthesized a reaction-based chemiluminescent probe for 
ONOO–, termed as PNCL. PNCL was constructed by linking a 1,2-dioxetane chemiluminescent 
scaffold with isatin through an ether linkage. Mechanistic studies revealed that isatin reacts 
directly with ONOO– instead of its downstream radicals. Isatin was used as a masking group 
which can be cleaved after reacting with ONOO– through an oxidative decarbonylation reaction 
to initiate the light emission. PNCL responds to ONOO– with high sensitivity and selectivity at 
physiological pH. We also provided some experimental support for the autooxidative product of 
HNO. PNCL has been applied for ONOO– detection from donor compounds in multiple cell 
lines, as well as cellular ONOO– generated by macrophages with LPS stimulation. Taken 
together, we have reported a useful tool, PNCL, to interrogate the biological functions of 
ONOO–. 
 
4.4. Experimental section 
4.4.1 Chemical synthesis 
 
5-iodo-3,3-dimethoxyindolin-2-one (13). 5-iodoisatin (203.1 mg, 7.43 mmol, 1.0 equiv) was 
dissolved in 300 mL MeOH, followed directly by the addition of 7.1 mL HCl. The reaction was 
stirred for 48 h at rt. The reaction mixture was neutralized with saturated NaHCO3, and then the 
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3 x 100 mL EtOAc. The organic layer was washed with 10 mL brine, dried over Na2SO4, 
filtered, and concentrated. Purification by silica column chromatography (1:4 EtOAc/hexanes) 
afforded 13 (2.2 g, 93%) as a colorless solid. 1H NMR (500 MHz, CDCl3) d 9.46 (s, 1H), 7.65 (d, 
1H, J = 1.7 Hz), 7.58 (dd, 1H, J = 8.0, 1.7 Hz), 6.70 (d, 1H, J = 8.0 Hz), 3.53 (s, 6H); 13C NMR 
(125 MHz, CDCl3) d 173.02, 140.40, 139.61, 133.84, 127.42, 113.36, 97.42, 85.43, 51.08. 
HRMS calcd for C10H10INO3 (M–H–) 317.9633, found 317.9638. 
 
3,3-dimethoxy-2-oxoindoline-5-carbaldehyde (14). Compound 13 (607.0 mg, 1.90 mmol, 1.0 
equiv), N-formyl saccharin (602.8 mg, 2.86 mmol, 1.5 equiv), palladium(II) acetate (12.8 mg, 
0.057 mmol, 0.03 equiv), 1,4-bis(diphenylphosphino)butane (36.5 mg, 0.086 mmol, 0.045 
equiv), and Na2CO3 (302.3 mg, 2.86 mmol, 1.5 equiv) were added to a 10 mL pressure flask. The 
flask was evacuated and backfilled with N2 three times. Then, a degassed solution of Et3SiH (395 
µL, 2.47 mmol, 1.3 equiv) and anhydrous DMF (2 mL) were added to the flask under N2. The 
pressure flask was sealed immediately and the mixture was stirred for 10 min at rt. Then the 
mixture was warmed to 80 °C and stirred for 16 h. The reaction was quenched with 100 mL 
saturated NH4Cl, extracted with 3 x 80 mL EtOAc, washed with 10 mL brine, dried over 
Na2SO4, filtered, and concentrated. The crude was purified by the silica column chromatography 
(1:3 EtOAc/hexanes) to deliver compound 14 as a white solid (245.0 mg, 59%). 1H NMR (500 
MHz, CDCl3) d 9.90 (s, 1H), 9.33 (s, 1H), 7.93 (d, 1H, J = 1.7 Hz), 7.87 (dd, 1H, J = 8.0, 1.7 
Hz), 7.07 (d, 1H, J = 8.0 Hz), 3.59 (s, 6H); 13C NMR (125 MHz, CDCl3) d 190.81, 173.33, 
146.20, 134.69, 131.82, 126.25, 125.85, 111.36, 96.60, 51.02. HRMS calcd for C11H11NO4 (M–
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5-(hydroxymethyl)indoline-2,3-dione (15). Compound 14 (160.0 mg, 0.72 mmol, 1.0 equiv) 
and sodium borohydride (41.9 mg, 1.11 mmol, 1.53 equiv) were dissolved in 12 mL EtOH, and 
the mixture was stirred at rt for 1 h. The reaction was quenched with 80 mL saturated NH4Cl, 
extracted with 3 x 40 mL EtOAc, washed with 10 mL brine, dried over Na2SO4, filtered, and 
concentrated to yield 5-(hydroxymethyl)-3,3-dimethoxyindolin-2-one (162 mg) as a colorless oil 
and used without further purification. 1H NMR (500 MHz, CDCl3) d 9.05 (s, 1H), 7.39 (s, 1H), 
7.24 (d, 1H, J = 8.0 Hz), 6.79 (d, 1H, J = 8.0 Hz), 4.61 (s, 2H), 3.53 (s, 6H); 13C NMR (125 
MHz, CDCl3) d 173.33, 140.14, 135.67, 129.81, 125.43, 124.28, 111.05, 97.41, 64.88, 50.95. 
HRMS calcd for C11H13NO4 (M–H–) 222.0772, found 222.0778. 5-(hydroxymethyl)-3,3-
dimethoxyindolin-2-one (189 mg, 0.85 mmol, 1.0 equiv) was dissolved in 12 mL 1 M HCl 
solution, and the reaction was stirred at rt for 30 min. The reaction was neutralized with saturated 
NaHCO3, and then the reaction mixture was poured into a separatory funnel, and extracted with 
3 x 40 mL 3:1 DCM: iPrOH and 3 x 30 mL EtOAc. The organic layer was washed with 10 mL 
brine, dried over Na2SO4, filtered, and concentrated. Purification by silica column 
chromatography (1:1 to 2:1 EtOAc/hexanes) afforded 15 (132.0 mg, 88%) as an orange solid. 1H 
NMR (500 MHz, (CD3)2CO) d 7.58 (d, 1H, J = 8.0 Hz), 7.50 (dd, 1H, J = 8.0, 1.7 Hz), 6.96 (d, 
1H, 1.7 Hz), 4.57 (s, 2H); 13C NMR (125 MHz, (CD3)2CO) d 184.09, 159.14, 149.60, 137.82, 
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 (E)-3-(4-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)-3-chloro-2-((2,3-
dioxoindolin-5-yl)methoxy)phenyl)acrylonitrile (17). Compound 15 (20 mg, 0.11 mmol, 1.0 
equiv), compound 16 (43.8 mg, 0.11, 1.0 equiv),26 and triphenylphosphine (36.0 mg, 0.13 mmol, 
1.2 equiv) were dissolved in 2 mL anhydrous THF, and the reaction mixture was cooled to 0 °C. 
Diethyl azodicarboxylate (21.3 µL, 0.14 mmol, 1.2 equiv) was added dropwise over 5 min. After 
1 h of stirring at rt, the mixture was concentrated. Purification by silica column chromatography 
(2% MeOH/DCM) afforded 17 as a yellow oil (49.0 mg, 84%). 1H NMR (500 MHz, CDCl3) d 
8.56 (s, 1H), 7.71 (dd, 1H, J = 8.0, 1.7 Hz), 7.64 (d, 1H, J = 1.7 Hz), 7.50 (d, 1H, J = 16.8 Hz), 
7.12 (d, 1H, J = 8.0 Hz), 7.02 (d, 1H, J = 8.0 Hz), 5.90 (d, 1H, J = 16.8 Hz), 4.98 (m, 2H), 3.32 
(s, 3H), 3.27 (s, 1H), 1.64-2.20 (m, 13 H); 13C NMR (125 MHz, CDCl3) d 182.76, 159.24, 
152.97, 149.62, 144.73, 139.66, 139.05, 133.50, 131.91, 129.98, 128.40, 125.88, 124.59, 118.24, 
117.98, 112.85, 98.63, 75.11, 57.56, 39.27, 39.12, 38.73, 37.05, 33.11, 29.85, 29.36, 28.38, 
28.21. HRMS calcd for C30H27ClN2O4 (M–H–) 513.1587, found 513.1595. 
 
(E)-3-(3-chloro-2-((2,3-dioxoindolin-5-yl)methoxy)-4-((1r,3r,5r,7r)-4'-
methoxyspiro[adamantane-2,3'-[1,2]dioxetan]-4'-yl)phenyl)acrylonitrile (PNCL). Enol ether 
17 (40.0 mg, 0.075 mmol, 1.0 equiv) and Rose bengal (9.8 mg, 0.010 mmol, 0.13 equiv) were 
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mixture, while irradiating with a 120 W light bulb (Home Depot, Dallas, TX) at 0 °C. After 3 h 
of reaction, TLC showed no starting material left and the mixture was then concentrated under 
vacuum at 0 °C and the residue was purified by the silica column chromatography (10:1 
DCM/Ether) to deliver PNCL (33.0 mg, 81%) as a yellow solid. 1H NMR (500 MHz, CDCl3) d 
9.02 (s, 1H), 7.97 (d, 1H, J = 8.6 Hz), 7.66-7.70 (m, 2H), 7.25-7.52 (m, 2H), 7.12 (d, 1H, J = 8.0 
Hz), 7.04 (d, 1H, J = 8.0 Hz), 5.96 (d, 1H, J = 16.6 Hz), 4.90 (s, 2H), 3.22 (s, 3H), 3.02 (s, 1H), 
1.24-2.20 (m, 13H); 13C NMR (125 MHz, CDCl3) d 182.77, 159.21, 153.45, 149.72, 144.23, 
138.94, 136.76, 131.60, 120.50, 129.62, 125.86, 124.77, 118.30, 117.65, 112.92, 111.63, 100.03, 
96.49, 75.26, 49.87, 36.58, 33.98, 33.72, 32.79, 32.23, 31.64, 31.05, 29.79, 26.18, 25.87; 
MALDI-MS calcd for C30H27ClN2O6 (M+H+) 547.16, found 547.15. 
 
4.4.2 Preparation of ONOO–46 
To a 200 mL flask was added 2.2 mL of 11.6 M H2O2 (26.0 mmol) further diluted with 
50 mL DI water. The mixture was allowed to chill to 0 °C before addition of 36 mL of 0.55 M 
NaOH followed by 5 mL of 0.04 M EDTA. The final mixture was diluted to a total volume of 
100 mL with DI water before the addition of 3.4 mL isopentyl nitrite (26.0 mmol). A deep, 
yellow color indicates formation of peroxynitrite. After 6 hours of stirring at 0 °C, the mixture 
was washed 3 x 20 mL with DCM. To the aqueous layer was added roughly 20 mg of MnO2. 
The mixture was allowed to stir until bubbling ceased, upon which it was filtered twice and 
stored on ice or in the freezer. The concentration was determined using an extinction coefficient 
of e = 1670 M–1 cm–1 at 302 nm. 
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4.4.3 GC-MS procedure to monitor reaction intermediates 
300 µL of 10 mM PNCL in DMSO (3 mM final concentration), and 125 µL of 48 mM 
ONOO– (6 mM final concentration) were mixed in an Eppendorf tube, and vortexed for 5 
second. The reaction mixture was then poured into a separatory funnel containing 10 mL EtOAc 
and 15 mL DI-H2O and extracted with 2 x 10 mL EtOAc. The organic layer was collected, dried 
over Na2SO4, filtered, and concentrated. Then the solid was re-dissolved in 2 mL CH2Cl2, 
transferred to a GC-MS vial and GC-MS was conducted immediately.  
 
4.4.4 Chemiluminescent response 
20 mM HEPES buffer (pH 7.4), 5 mM PNCL stock solution in DMSO and ONOO– were 
added to a quartz cuvette in sequences. Samples were shaken gently to assure mixing. 20 µM 
PNCL was treated with 0, 5, 10, 20, 40, 80, 100 and 200 µM ONOO–. Time scans were acquired 
using the time scan module by setting the emission wavelength to 525 nm. Wavelength scans 
were acquired by treating 20 µM PNCL with 0 µM to 200 µM ONOO–. Time scans and 
wavelength scans were measured 10 second after adding ONOO–. 
 
4.4.5. Determination of the detection limit of bolus ONOO– 
Chemiluminescent responses were measured using a Cytation 5 BioTek plate reader 
(Winooski, VT) by using the luminescence detection method, endpoint read type, and setting 
gain to 135 and temperature to 37 °C. 0.125 mM, 0.25 mM, 0.5 mM, 0.75 mM ONOO– stock 
solutions were made by dilution of a 16 mM ONOO– solution with 0.01 M NaOH, and the final 
concentration was also confirmed by UV/Vis. 249 µL of 10 mM PBS buffer (pH 7.4) was added 
into vehicle well, and 248 µL of 20 mM HEPES buffer (pH 7.4) was added into other wells. 1 µL 
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of 5 mM PNCL was pipetted into every well, and then 1 µL of different concentrated ONOO– 
stock solutions were added into wells. The chemiluminescence emission was then measured on 
the plate reader. The emission was integrated over 30 minutes and the calibration curve was 
constructed using three replicate experiments. The detection limit was determined as LoD = 
3s/k. 
 
4.4.6 Structure-activity studies 
Fluorescence response. 5 mM isatin and 30 mM SIN-1 in DMSO were prepared before testing. 10 
µL of 5 mM isatin (50 µM final concentration) and 16.7 µL of 30 mM SIN-1 (500 µM final 
concentration) were added into 973.3 µL of 20 mM HEPES buffer (pH = 7.42), and fluorescence 
response was taken 1 min after addition with excitation wavelength at 320 nm. Isatin derivatives, 
N-methyl isatin, N-phenyl isatin, and isatin dimethyl acetal were prepared in DMSO with final 
concentrations of 5 mM. 10 µL of 5 mM isatin or its derivatives (50 µM final concentration) was 
added into a cuvette with 983 µL HEPES buffer, and then 6.62 µL of 30.2 mM ONOO– (200 µM 
final concentration) was added into the mixture. Wavelength spectra were measured 1 min after 
adding ONOO– with excitation wavelength at 320 nm. 
 
Inhibition experiments with HCO3– and TEMPOL. Different volumes of 100 mM HCO3– or 
TEMPOL in DI-H2O (0 µL, 2 µL, 5 µL, 10 µL and 50 µL) were added to the 20 mM HEPES buffer 
in the presence of 10 µL of 5 mM isatin (50 µM final concentration) in DMSO, followed by adding 
5.29 µL of 37.9 mM ONOO– (200 µM final concentration). The cuvette was shaken gently to 
assure mixing. Then, fluorescence spectra were acquired 1 min after addition with excitation 
wavelength at 320 nm.  
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4.4.7 Selectivity tests 
Selectivity for PNCL was measured by monitoring the time-dependent 
chemiluminescence emission at 525 nm with an F-7000 fluorescence spectrophotometer 
(Hitachi, Tokyo, Japan). All assays were performed in 20 mM HEPES buffered to pH 7.42. All 
analytes were tested with final concentration of 200 µM, with the exceptions of GSH (5 mM), 
and L-cysteine (1 mM).  
ONOO– (200 µM): 3.1 µL of 65 mM ONOO– was added to a solution of 993 µL HEPES buffer 
and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
S2O32– (200 µM): 4 µL of 50 mM Na2S2O3 in DI-H2O was added to a solution of 992 µL HEPES 
buffer and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
tBuOOH (200 µM): 4 µL of 50 mM tBuOOH in DI-H2O was added to a solution of 992 µL 
HEPES buffer and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
S-nitrosoglutathione (200 µM): 20 µL of 10 mM S-nitrosoglutathione in DI-H2O was added to a 
solution of 976 µL HEPES buffer and then 4 µL of 5 mM PNCL in DMSO was added to the 
mixture. 
GSH (5 mM): 20 µL of 250 mM GSH in DI-H2O was added to a solution of 976 µL HEPES 
buffer and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
L-Cysteine (1 mM): 4 µL of 250 mM cysteine in DI-H2O was added to a solution of 992 µL 
HEPES buffer and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
NaNO2 (200 µM): 4 µL of 50 mM NaNO2 in DI-H2O was added to a solution of 992 µL HEPES 
buffer and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
Na2SO4 (200 µM): 4 µL of 50 mM Na2SO4 in DI-H2O was added to a solution of 992 µL HEPES 
buffer and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
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Na2S (200 µM): 4 µL of 50 mM Na2S in DI-H2O was added to a solution of 992 µL HEPES 
buffer and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
H2O2 (200 µM): 4 µL of 50 mM H2O2 in DI-H2O was added to a solution of 992 µL HEPES 
buffer and then 4 µL of 5 mM PNCL in DMSO was added to the mixture. 
NO• (200 µM): DEA NONOate was used to generate NO. It was stored at –20 °C and dissolved 
in 0.01 M NaOH solution immediately prior to use. The concentration of this alkaline stock 
solution of DEA NONOate was measured by UV/Vis using e = 6500 M–1 cm–1 at 250 nm. 6.36 
µL of 31.45 mM DEA NONOate in 0.01 M NaOH solution was added to a 994 µL solution of 20 
µM PNCL in HEPES buffer. 
HNO (200 µM): Angeli’s salt (Na2N2O3) was used to generate HNO. The stock solution was 
made by dissolving Angeli’s salt in 0.01 M NaOH solution immediately prior to use. The 
concentration of this alkaline stock solution of Angeli's salt was measured by UV/V is using e = 
6100 M–1 cm–1 at 237 nm. 6.33 µL of 31.55 mM stock solution of H2O2 in DI-water was added to 
a 994 µL solution of 20 µM PNCL in HEPES buffer. 
O2•– (200 µM): 1 mg KO2 (final concentration 200 µM) was added to a 70 mL solution of 20 µM 
PNCL in HEPES buffer. 
OH• (200 µM): 1 mg Fe(ClO4)2 (final concentration 200 µM) was added to a 30 mL solution of 
20 µM PNCL and H2O2 (final concentration 200 µM) in HEPES buffer. 
OCl– (200 µM): 4 µL of 50 mM NaOCl in DI-H2O was added to a solution of 992 µL HEPES 
and 4 µL of 5 mM PNCL in DMSO was added into this mixture. 
Blank: 3.1 µL of a 0.20 M NaOH in DI-H2O was added to a solution of 993 µL HEPES and 4 µL 
of 5 mM PNCL in DMSO was added into this mixture. 
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OH• interference: 4 µL of 50 mM FeCl2 and 4 µL of 50 mM H2O2 were added to a solution of 
984 µL HEPES buffer containing 20 µM PNCL. 4 µL of 50 mM ONOO– was then added to that 
solution, and the mixture was shaken gently before testing. 
 
4.4.8 Synthesis of XF1 
3 - Oxo - 3H - spiro [isobenzofuran - 1, 9' - xanthene]- 3', 6' - diyl bis (2 - 
(diphenylphosphanyl)benzoate) (XF1). 2-(diphenylphosphino) benzoic acid (336.9 mg, 1.1 
mmol, 2.2 equiv) and HBTU (417.2 mg, 1.1 mmol, 2.2 equiv) were dissolved in 5 mL of DMF. 
DIPEA (0.52 mL, 3.0 mmol, 6.0 equiv) was added and the reaction was stirred for five minutes. 
Fluorescein (166.2 mg, 0.5 mmol, 1.0 equiv) was added and the reaction was stirred for 24 h. 
The reaction mixture was concentrated and purified by silica gel column chromatography (1:1 
Hexanes/EtOAc) to yield XF1 (78.4 mg, 17% yield) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 8.25–8.23 (m, 2H), 8.01 (d, 1H, J = 7.5 Hz), 7.66 (td, 1H, J = 7.5, J = 1.2 Hz), 7.61 (td, 
1H, J = 7.5, J = 1.2 Hz), 7.49–7.45 (m, 4H), 7.35–7.25 (m, 20H), 7.12 (d, 1H, J = 7.4 Hz), 7.01–
6.98 (m, 2H), 6.90 (d, 2H, J = 2.3 Hz), 6.74 (d, 2H, J = 8.6 Hz), 6.63 (dd, 2H, J = 8.6 Hz, 2.3 
Hz); 13C NMR (125 MHz, CDCl3) δ 169.53, 164.86, 153.29, 151.93, 151.48, 137.53, 137.45, 
135.35, 134.56, 134.20, 134.04, 133.08, 132.93, 132.86, 131.92, 131.52, 130.06, 129.28, 128.97, 
128.89, 128.74, 128.68, 128.45, 126.07, 125.23, 124.24, 117.85, 116.43, 110.59, 81.85; HRMS 
calcd for C58H38O7P2 [M+Na]+ 931.1985, found 931.1990. 
 
4.4.9 XF1 response and selectivity tests 
Response. Wavelength scan of fluorescent emission of 10 µM XF1 at 488 nm before and after 
adding 200 µM Angeli's salt were acquired in 20 mM HEPES buffer (pH 7.42). 996 µL HEPES 
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was added to an Eppendorf tube, then 2 µL of 5 mM XF1, and 2.3 µL of 86 mM Angeli's salt were 
added. The mixtures were vortexed for 5 seconds. The reaction was monitored every 5 minutes for 
30 minutes. 
Selectivity. Selectivity for XF1 was performed by treating it with various reactive species (5 mM 
GSH and 200 µM for other species) by monitoring fluorescent change every 5 minutes for 30 
minutes with excitation wavelength at 488 nm. Stock solution was prepared as 5 mM in DMSO 
and the selectivity reactions were performed in 20 mM HEPES (pH 7.42). 
 
4.4.10 Inhibition experiments with HCO3– and GSH 
Inhibition of response by GSH. Different volumes of 50 mM GSH in DI-H2O (0 µL, 1 µL, 2 µL, 
4 µL and 20 µL) were added to the 20 mM HEPES buffer in the presence of 4 µL of 5 mM 
PNCL in DMSO (20 µM final concentration), followed by adding 5.2 µL of 38.4 mM ONOO– 
(200 µM final concentration) or 1.2 µL of 172.7 mM Angeli’s salt (200 µM final concentration). 
The cuvette was shaken gently to assure mixing. Then time scans were acquired using the time 
scan module with emission wavelength at 525 nm.  
Inhibition of response by HCO3–. Different volumes of 50 mM NaHCO3 in DI-H2O (0 µL, 20 µL, 
40 µL, 60 µL, 80 µL and 100 µL) were added to the 20 mM HEPES buffer in the presence of 4 
µL of 5 mM PNCL in DMSO (20 µM final concentration), followed by adding 5.2 µL of 38.4 
mM ONOO– (200 µM final concentration) or 1.1 µL of 177.4 mM Angeli’s salt (200 µM final 
concentration). The cuvette was shaken gently to assure mixing. Then time scans were acquired 
using the time scan module with emission wavelength at 525 nm. 
Inhibition experiments for XF1. Different volumes of 50 mM GSH in DI-H2O (0 µL, 1 µL, 2 µL, 
4 µL and 20 µL) or different volumes of 50 mM NaHCO3 in DI-H2O (0 µL, 20 µL, 40 µL, 60 
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µL, 80 µL and 100 µL)were added to the 20 mM HEPES buffer in the presence of 2 µL of 5 mM 
XF1 (10 µM final concentration) in DMSO, followed by adding 1.2 µL of 172.7 mM Angeli’s 
salt. The cuvette was shaken gently to assure mixing. Then time scans were acquired using the 
time scan module with emission wavelength at 525 nm.  
 
4.4.11 Cell culture  
Macrophages (RAW 264.7) were purchased from ATCC and cultured in high glucose 
Dulbecco's Modified Eagle Media (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) 
and 1% antibiotics (penicillin/streptomycin, 100 U/mL). Cells were maintained in a humidified 
incubator at 37 °C with 5% CO2. 12 hours before the experiment, cells were passed and plated on 
multi-well plates by adding 1000K–1500K of macrophages per well, filling each well with 1 mL 
of media.  
Human lung adenocarcinoma epithelial cell (A549) were purchased from ATCC and 
cultured in F-12K media supplemented with 10% Fetal Bovine Serum (FBS) and 1% antibiotics 
(penicillin/streptomycin, 100 U/mL). Cells were maintained in a humidified incubator at 37 °C 
with 5% CO2. Two days before the experiment, cells were passed and plated on Costar® 12-well 
plates by adding 150K–200K of A549 cells per well, filling each well up to 1 mL of media. 
Chemiluminescent responses and MTT absorption were measured using a Cytation 5 BioTek plate 
reader (Winooski, VT). Fluorescence imaging was conducted using an EVOS-fl fluorescent 
microscope (Advanced Microscopy Group) equipped with a GFP filter cube. 
 
  136 
4.4.12 MTT assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay: RAW 264.7 
macrophage cells (106 cell/mL) were seeded in a 96-well plate to a total volume of 100 µL/well. 
The plate was maintained at 37 °C with 5% CO2 for 12 h. Cells were then incubated for 24 h 
after adding different concentrations of PNCL, 0, 0.1, 1, 10, 100 and 1000 µM respectively. 10 
µL of the MTT reagent (Cayman Chemical, Ann Arbor, MI) was then added to each well, and 
mixed gently. After 4 h incubation, 100 µL of crystal dissolving solution was added to each well 
to dissolve the formazan crystals. Absorbance was measured at 570 nm in a Cytation 5 BioTek 
plate reader.47 
 
4.4.13 Cellular internalization of PNCL 
RAW 264.7 macrophage cells (106 cell/mL) were seeded in a 12-well plate to a total 
volume of 1 mL/well. Plate was maintained at 37 °C with 5% CO2 for 12 h. Prior to imaging, the 
medium was removed and cells were washed with 2 x 1 mL PBS, and each well was filled with 
992 µL of PBS. Then, 8 µL of 5 mM PNCL in DMSO (40 µM final concentration) or 8 µL 
DMSO was added. The plate was imaged on an EVOS-fl fluorescent microscope using a GFP 
filter set after 10 min incubation. 
 
4.4.14 Detection of SIN-1 generated ONOO– in living cells 
Detection of SIN-1 generated ONOO– in macrophages. RAW 264.7 macrophage cells (106 
cell/mL) were seeded in a 12-well plate to a total volume of 1 mL/well. Prior to imaging, the 
medium was removed and cells were washed with 1 x 1 mL PBS. Each well was filled with 996 
µL of FluoroBrite DMEM Media. Then, 4 µL of 5 mM PNCL in DMSO (20 µM final 
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concentration) was added to each well, and incubated for 30 min. After incubation, the media 
was removed and cells were washed with 2 x 1 mL PBS. Different amount of PBS media was 
added into each well to make the final volume equal to 1 mL. Different volumes of 50 mM SIN-
1 in DMSO (0 µL, 8 µL, 16 µL, 20 µL, and 40 µL) were added into each well. Different volume 
of DMSO was added into each well to make each well have same amount of DMSO. Then 
luminescence response was measure by the Cytation 5 BioTek plate reader by using the 
luminescence detection method, endpoint read type, and setting gain to 135 and temperature to 
37 °C. 
 
Detection of SIN-1 generated ONOO– in A549 cells. Human lung adenocarcinoma epithelial cell 
(A549) were plated in a 12-well plate to a total volume of 1 mL/well. The media was removed 
upon 90–95% confluence. Each well was washed with 1 x 1 mL PBS, and each well was filled 
with 996 µL of FluoroBrite DMEM Media. Then, 4 µL of 5 mM PNCL in DMSO (20 µM final 
concentration) was added to each well, and incubated for 30 min. After incubation, the media 
was removed and cells were washed with 2 x 1 mL PBS. Different amount of PBS media was 
added into each well to make the final volume equal to 1 mL. Different volumes of 50 mM SIN-
1 in DMSO (0 µL, 8 µL, 16 µL, 20 µL, and 40 µL) were added into each well. Different volume 
of DMSO was added into each well to make each well have same amount of DMSO. Then 
luminescence response was measure by the plate reader. 
 
Scavenger experiment in macrophages. Macrophages were washed with 1 x 1 mL PBS, and each 
well was filled with 996 µL of FluoroBrite DMEM Media. Then, 4 µL of 5 mM PNCL in 
DMSO (20 µM final concentration) was added to each well, and incubated for 30. The media 
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was removed after incubation and cells were washed with 2 x 1 mL PBS. Different amount of 
PBS media was added into each well to make the final volume equal to 1 mL. 40 µL of 50 mM 
SIN-1 in DMSO, 1.4 µL or 2.8 µL of 2 mg/ mL Mn(III)TMPyP were added. 
 
4.4.15 Application of PNCL for detecting endogenous ONOO– 
0.1 mg/mL LPS was prepared in DI-H2O, and 2 mg/mL Mn(III)TMPyP solution was 
made in 20 mM PBS buffer (pH = 7.42) on the same day of the test. Prior to imaging, media was 
removed from macrophages and macrophages were washed with 1 x 1 mL PBS, and each well 
was filled with FluoroBrite DMEM Media. 10 µL of LPS (1000 ng/mL final concentration) were 
added to experimental wells, and 10 µL of DI-H2O was added to control wells. After 16 h 
incubation, 4 µL of 5 mM PNCL (20 µM final concentration) was added to each well, and 
incubated for another 30 min. After incubation, the media was removed and cells were washed 
with 2 x 1 mL PBS, and vehicle or 25 µM Mn(III)TMPyP was added to the appropriate wells. 
Then the luminescence response was measured every 10 minutes over 4 hours. 
 
4.4.16 iNOS inhibition of the production of ONOO– in macrophages 
0.1 mg/mL LPS and 10 mg/mL 1400W (Cayman Chemical, Ann Arbor, MI) were 
prepared in DI-H2O on the same day of the test. Prior to imaging, media was removed from 
macrophages and cells were washed with 1 x 1 mL PBS, and each well was filled with 
FluoroBrite DMEM Media. 10 µL of LPS (1000 ng/mL final concentration) and 5 µL of 1400W 
(200 µM final concentration) were added to the appropriate wells. The control was performed by 
adding 15 µL DI-H2O. After 16 h incubation, 4 µL of 5 mM PNCL (20 µM final concentration) 
was added to each well, and incubated for another 30 min. The media was removed and cells 
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were washed with 2 x 1 mL PBS. 5 µL of 1400W were added for the inhibition tests. Then the 
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APPENDIX I. 
ENHANCER FREE CHEMILUMINESCENT PROBE FOR HYPOXIA 
 







nitrobenzyl)oxy)phenyl)acrylonitrile (18). 15 (85 mg, 0.218 mmol, 1.0 equiv), triphenyl 
phosphite (69 mg, 0.262 mmol, 1.2 equiv) and 4-nitrobenzyl alcohol (33 mg, 0.218 mmol, 1.0 
equiv) were added to a dry round bottom flask flushed with nitrogen.  The reaction contents were 
dissolved in 3.0 mL THF, and was cooled to 0° C. diethylazodicarboxylate (41 µL, 0.262 mmol, 
1.2 equiv) was added dropwise to the solution, and stirred for 1 hr.  The crude mixture was 
combined with 30 mL brine solution, and mixture was washed with 2 x 20 mL EtOAc.  The 
combined organic layers were collected and dried over Na2SO4, filtered, and concentrated under 
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mg, 92%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) d 8.29 (d, 2H, J = 8.6 Hz), 7.62 (d, 
1H, J = 16.5 Hz), 7.38 (d, 1H, J = 8 Hz), 7.14 (d, 1H, J = 8 Hz),  5.97 (d, 1H, J = 16.5 Hz), 5.03-
5.15 (m, 2H), 7.04 (d, 1H, J = 8.0 Hz), 5.96 (d, 1H, J = 16.6 Hz), 3.34 (s, 3H), 3.27 (s, 1H), 1.64-
2.20 (m, 13 H); 13C NMR (125 MHz, (CD3)2CO) d 152.95, 147.92, 144.26, 142.93, 139.57,  
138.95, 133.51, 129.76, 128.41, 128.26, 124.60, 123.89, 117.80, 99.00, 74.36, 57.59, 39.16, 39.9
9, 38.62, 28.53, 36.91, 32.98, 29.72, 28.24, 28.08. 
 
HyCL-3. Compound 18 (40 mg, .081 mmol, 1.0 equiv) and Rose bengal (8.5 mg, 0.0087 mmol, 
0.107 equiv) were added into a dry flask and dissolved in 5 mL THF. Oxygen was bubbled 
through the reaction mixture, while irradiating with a 120 W light bulb (Home Depot, Dallas, 
TX) at 0 °C. After 3.5 h of reaction, TLC showed no starting material left and the mixture was 
then concentrated under vacuum at 0 ºC and the residue was purified by column chromatography 
(1:15 EtOAc/hexanes) to deliver HyCL-3 as a white solid (56.4 mg, 87 %). 1H NMR (500 MHz, 
CDCl3) d 8.31 (d, 2H, J = 8.6 Hz), 8.00 (d, 1H, J = 8.6 Hz), 7.67 (d, 2H, J = 8.6 Hz), 7.60 (d, 1H, 
J = 16.6), 7.54 (d, 1H, J = 8.0 Hz), 5.02 (s, 2H), 3.22 (s, 3H), 3.02 (s, 1H), 1.24-2.20 (m, 13H); 
13C NMR (125 MHz, CDCl3) d 153.53, 148.11, 143.86, 136.79, 130.33, 129.77, 128.37, 127.94,  
124.92, 124.01, 117.55, 111.58, 100.59, 96.44, 74.54, 49.86, 37.03, 36.57, 33.96, 33.73, 32.23, 3
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4-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)-3-chloro-2-hydroxybenzaldehyde 
(21). Iodine phenol 20 (400 mg, 0.93 mmol, 1.0 equiv), N-formylsaccharine  (296 mg, 1.40 
mmol, 1.5 equiv), sodium carbonate (148 mg, 1.40 mmol, 1.5 equiv) palladium acetate (6.2 mg, 
0.028 mmol, 0.03 equiv), and 1,4-bis(diphenylphosphino) butane (17 mg, 0.04 mmol, 0.045 
equiv) were added to a 10 mL pressure flask, and a small stir bar was added.  The flask was 
evacuated and back-filled with N2 three times. The contents were dissolved in 4 mL anhydrous 
DMF.  Triethyl silane (193 µL, 1.21 mmol, 1.3 equiv) was then added, and the reaction was 
immediately sealed and stirred for 10 min. The mixture was brought up to 80 °C and stirred for 
16 hr.  The reaction was quenched with 50 mL NH4Cl, and extracted with 3 x 30 mL EtOAc.  
The combined organic layers were dried with Na2SO4, and concentrated under reduced pressure.  
Column chromatography (10% EtOAc/ Hexanes) afforded compound 6 (263 mg, 85 %) as a 
yellow solid. 1H NMR (500 MHz, CDCl3) d 11.66 (s, 1H), 9.93 (s, 1H), 7.50 (d, 1H, J = 8.0 Hz), 
7.00 (d, 1H, J = 8.0 Hz), 3.36 (s, 3H), 3.32 (s, 1H), 1.24-2.20 (m, 13H); 13C NMR (125 MHz, 
CDCl3) d 195.83, 157.62, 143.58, 138.95, 133.49, 131.03, 122.99, 120.47, 57.63, 39.32, 39.12,  
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In vitro characterization.  
 
 
Figure 1A-1. Response of HyCL-3 to nitroreductase. (a) Chemiluminescence emission spectra 
of 10 µM HyCL-3 before (blue trace) and after (red) trace adding 14 (red trace) µg/mL 
nitroreductase in the presence of 0.4 mM NADH. (b) Time scans of the chemiluminescence 
emission at 525 nm of 10 µM HyCL-3 and 0 (blue trace), 5 and 0, 2.5, 5, 7.5, 10, 12.5, 14 (red 
trace) µg/mL nitroreductase in the presence of 0.4 mM NADH in 10 mM PBS buffer (pH 7.4). 
 
 
Figure 1A-2. Chemiluminescent responses of 10 µM HyCL-3 to biologically relevant analytes 
in 10 mM PBS buffer (pH 7.4) containing 10% Emerald II Enhancer. Bars represent 
chemiluminescence emission at 545 nm and 4, 8, 12, 16, 20 min after addition of reducing 
agents. Data shown are for 5 mM GSH, 1 mM cysteine and hcy, and 200 µM for other reducing 
agents. (1) nitroreductase and NADH; (2) GSH; (3) L-cysteine; (4) hcy; (5) nitroreductase; (6) 
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APPENDIX II.  
SCANNED 1H AND 13C NMR SPECTRA 
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